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ABBREVATIONS 
AB: acid box 
ADAM: A Disintegrin and Metalloproteinase 
AKT: Protein Kinase B (PKB) 
ANG II: Angiotensin II 
APC: Adenomatous Polyposis Coli 
AR: Amphiregulin 
BRCA1: Breast Cancer 1 
BSA: Bovin Serum Albumin 
BTC: Betacellulin 
cDNA: complementary DNA 
CK1: Casein kinase 1 
COX-2: Cyclooxygenase-2 
CRE: cAMP response element 
CREB: CRE binding protein 
CTNNB1: human β-catenin gene 
CYP7A1: Cholesterol 7a-hydroxylase 
DEPC: Diethyl pyrocarbonate 
DKKs: Dickkpf proteins 
DMEM: Dulbecco’s Modified Eagle Medium 
DNA: Deoxyribonucleic acid 
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DUSP: Dual Specifity Phosphatase 
EGF: Epidermal Growth Factor  
EGFR: Epidermal Growth Factor Receptor 
ELISA: Enzyme-Linked ImmunoSorbent Assay 
EPG: Epigen 
EPR: Epiregulin 
FBS: Fetal Bovine Serum 
FGF: Fibloblast Growth Factor  
FGFR: Fibloblast Growth Factor Receptor 
FRS2: FGF Substrate 2 
Frs2a: Fibroblast growth factor Receptor substrate 2 
Fz: Frizzled  
Gab1: Grb2-associated binding protein 1 
GEO: Gene Expression Omnibus 
GPCR: G Protein-Coupled Receptor 
GRB2: Growth factorRreceptor-Bound 2 
GS: Glutamine Synthetase 
GSK3β: Glycogen Synthase Kinase 3 beta 
HB-EGF: Heparin-binding Growth Factor 
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HCC: Hepatocellular Carcinoma 
HCV: Hepatitis C viral 
HER: Human Epidermal Receptor 
HGF: Hepatocyte Growth Factor 
HS: Heparin Sulfate 
HSP70: Hot Shot Protein 70 
HSPGs: Heparan sulfate proteoglycans 
Ig: Immunoglobuline 
IGF: Isulin-like Growth Factor 
IGF1R: Isulin-like Growth Factor 1 Receptor 
IL-1b: Interleukin-1b 
INM: Inner Nuclear Membrane 
INTγ: Interferon γ 
KL: Klotho 
KLB: β-Klotho 
LPA: Lysophosphatidic acid 
LRPs: Low-density lipoprotein receptor related proteins  
MAPK: Mitogen-Activated Protein Kinase 
MMPs: Metalloproteasas 
mRNA: Messenger RNA 
NFAT: Nuclear Factor of Ativated T cells 
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NRGs : Neuregulins 
NSCLC: Non-Small-Cell Lung Cancer 
PCP: Planar Cell Polarity 
PCR: Polymerase Chain Reaction  
PDGFR: Platelet-derived growth factor receptors 
PGE2: Prostaglandine 2 
PI3K: Phosphatidylinositol 3-kinase 
PKC: Protein Kinase C 
PLCγ: Phospholipase C γ 
PMA: Phorbol ester-12-Myristate-13-Acetate 
qPCR: Real Time PCR 
RNA: Ribonucleic acid 
ROK: Rho-associated protein 
ROS: Reactive oxygen species 
SDS: Sodium Dodecyl Sulfate 
Sef: Similar Expression to FGF 
Ser: Serine 
sFRP: Secreted Frizzled-related protein 
Shp2: Src homology region 2 domain containing phosphatase 2 
SOS: Son of Sevenless 
STAT: Signal Transducers and Activators of Transcription 
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TBEs: Tcf-binding elements 
TCF/LEF: T cell factor/lymphoid enhancer factor 
TE: Tris-EDTA 
TGFα: Transforming Growth Factor α 
Thr: Threonine 
TKIs: Tyrosine kinase inhibitors 
TMB: 3,3’,5,5’-tetramethylbenzidine 
TNF-α: Tumor Necrosis Factor α 
VEGF: Vascular Endothelial Growth Factor 
WIF-1: Wnt Inhibitory Factor-1 
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Hepatocellular carcinoma (HCC) is the most prevalent liver tumor and a deadly disease 
with limited therapeutic options. Dysregulation of cell signalling pathways is a common 
denominator in tumorigenesis, including hepatocarcinogenesis. The epidermal growth 
factor receptor (EGFR) signalling system is commonly activated in HCC, and is currently 
being evaluated as a therapeutic target in combination therapies. We and others have 
identified a central role for the EGFR ligand amphiregulin (AR) in the proliferation, 
survival and drug resistance of HCC cells. AR expression is frequently up-regulated in HCC 
tissues and cells through mechanisms not completely known. Here we identify the β-
catenin signalling pathway as a novel mechanism leading to transcriptional activation of 
the AR gene in human HCC cells. Activation of β-catenin signalling, or expression of the 
T41A β-catenin active mutant, led to the induction of AR expression involving three 
specific β-catenin/T cells Factor (Tcf) responsive elements in its proximal promoter. We 
demonstrate that HCC cell expressing the T41A β-catenin active mutant show enhanced 
proliferation that is dependent on AR expression and EGFR signalling. We also 
demonstrate here a novel crosstalk of the EGFR system with fibroblast growth factor 19 
(FGF19). FGF19 is a recently identified driver gene in hepatocarcinogenesis and an 
activator of β-catenin signalling in HCC and colon cancer cells. We show that FGF19 
induced AR gene expression through the β-catenin pathway in human HCC cells. 
Importantly, AR up-regulation and EGFR signalling were necessary for the induction of 
cyclin D1 and cell proliferation by FGF19. Finally, we demonstrate a positive correlation 
between FGF19 and AR expression in human HCC tissues, therefore validating in clinical 
samples our experimental observations. These findings identify the AR/EGFR system as a 
key mediator of FGF19 responses in HCC cells involving β-catenin signalling, and suggest 
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1. Hepatocellular Carcinoma (HCC)  
1.1. Epidemiology of HCC  
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. 
Globally, it ranks fifth among the most common cancers but it is the third leading cause of 
cancer death, with an estimate of more than 500000 new cases every year (Ferlay et al. 
2000; Parkin et al. 2000). There is a striking geographical difference in the incidence of 
HCC. Eighty per cent of new cases occur in developing countries. High-incidence areas 
include the sub-Saharan Africa, east and Southeast Asia, whereas low incidence areas 
include northern and western Europe and North America. Better control of the risk factors 
has resulted in a recent decline in HCC in some places such as Taiwan and China (Lee CL et 
al. 2003a). However, recently there is a trend of rising rates of HCC in developed countries 
in Europe and North America (El-Serag HB 2004). In Southeast Asia, HCC is the second 
most common fatal cancer. It has been the second most common fatal cancer and its 
ranking among the common causes of fatal cancers has not changed since the 1970s. A 
male predominance is obvious, with a male to female ratio of 2–4:1 (El-Serag and Rudolph 
2007). 
The risk factors of HCC are well established and include chronic hepatitis B viral (HBV) 
and hepatitis C viral (HCV) infection (Anzola 2004), cirrhosis (Fattovich et al. 2004) and 
Aflatoxin B1- contaminated food (Yu and Yuan 2004). 
Alcohol abuse leading to cirrhosis increases HCC risk appreciably by promoting liver 
cirrhosis; only severe, but not moderate, alcohol consumption is related to HCC 
(Mandayam S et al. 2004). The role of tobacco smoking in the causation of HCC is 
controversial. Other risk factors include inherited metabolic diseases such as hereditary 
haemochromatosis (Kowdley 2004), α-1-antitrypsin deficiency and hereditary 
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an established risk factor for HCC, most likely via progression of the steatohepatitic 
disease to cirrhosis and HCC (Calle et al. 2003). 
 
Figure 1: Mechanisms of hepatocarcinogenesis. (From Farazi and DePinho 2006) 
1.2 Molecular pathogenesis 
Hepatocarcinogenesis is a multistep process that could last for decades and involves 
the progressive accumulation of different genetic and epigenetic alterations ultimately 
leading to malignant transformation. Some of the molecular steps involved in the 
development of HCC have been elucidated in the past few years (Anthony 2002; 
Pachiadakis et al. 2005; Park et al. 2003; Majumder et al. 2002; Foy et al. 2005; Li et al. 
2005). HCCs are phenotypically and genetically very heterogeneous, and this 
heterogeneity might partially reflect the heterogeneity of aetiological factors that are 
implicated in the development of HCC, the complexity of hepatocyte functions and the late 
stage at which HCC usually becomes clinically symptomatic and detectable. The diverse 
HCC-inducing aetiologies provoke continuous rounds of hepatocyte damage and 
regeneration, culminating in chronic liver disease (Gale and Foy 2005) (Figure 2). 
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represent a potential first step towards HCC. These lesions can progress to pre-malignant 
dysplastic nodules, which have abnormal cytological features including clear cell changes 
and nuclear crowding, and these lesions are associated with the increased thickening of 
the trabeculae, which indicates abnormal liver architecture. These dysplastic nodules can 
evolve to frank HCC which, in addition to all the aforementioned abnormal features, is 
endowed with the capacity to invade the surrounding fibrous stroma and vessels, and 
occasionally has metastatic potential (Okuda 2000). Although considerable progress has 
been made in understanding the sequence of events that lead to other forms of cancer, 
most notably for colorectal cancer and certain hematopoietic malignancies, the molecular 
factors that are involved in hepatocellular carcinogenesis are still poorly understood. 
Increased turnover of liver cells and the malignant transformation of hepatocytes may 
occur in response to various stimuli, for example chronic liver injury, cellular regeneration 
in the context of inflammation, or in response to oxidative DNA damage. These stimuli can 
result in genetic and epigenetic alterations, such as the activation of cellular oncogenes 
and the inactivation of tumor suppressor genes, possibly in conjunction with the induction 
of genomic instability, such as DNA mismatch repair defects and impaired chromosomal 
segregation. Such defects may lead to the disruption of signaling pathways and could, for 
example, cause the overexpression of growth factors or growth-factor receptors, which 
might result in increased resistance of the cell to apoptosis, the stimulation of 
angiogenesis, hepatocyte proliferation and invasion or metastasis (Anthony 2002; 
Murakami et al. 2005; Pachiadakis et al. 2005; Park et al. 2003; Majumder et al. 2002; Foy 
et al. 2005; Li et al. 2005; Hino et al. 2002; Macdonald et al. 2003; Majumder et al. 2001; 
Moriya et al. 2001). Evidences suggest that HBV and perhaps also HCV might have a direct 
role in the molecular pathogenesis of HCC through interactions with cellular components. 
Various viral proteins interact with growth-factor signaling cascades involved in the 
control of cell proliferation, migration and apoptosis (Kamegaya et al. 2005). In addition, 
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mechanism by which other environmental factors might contribute to tumor development 
at the molecular level. A study that used a transgenic mouse model demonstrated that the 
presence of chronic liver cell injury induced by an abnormal immune response is sufficient 
to cause HCC, even in the absence of viral transactivation, insertional mutagenesis or 
genotoxic chemicals (McClain et al. 2002). Furthermore, neutralization of Fas ligand 
activity by anti-Fas-ligand antibody therapy prevented hepatocyte apoptosis and 
increased proliferation and liver inflammation, which eventually led to the development of 
HCC in this rodent model (Hoek and Pastorino 2002) a study in another transgenic mouse 
model demonstrated that the transcription factor NFκB is essential for promotion of 
inflammation associated cancer; (Campbell et al. 2005; Comporti et al. 2005) NFκB is, 
therefore, a potential target for cancer prevention in chronic inflammatory disease. 
Finally, polymorphisms in enzymes that are responsible for drug metabolism, such as the 
cytochrome P450 oxidases, N-acetyltransferases and glutathione-S-transferase, might also 
contribute to the genetic susceptibility of an individual to development of HCC (Osna et al. 
2005). 
Furthermore telomere shortening has been described as a key feature of chronic 
hyperproliferative liver disease, specifically occurring in the hepatocyte compartment 
(Kitada et al. 1995). These observations have fueled speculation that telomere shortening 
associated with chronic liver disease and hepatocyte turnover contribute to the induction 
of genomic instability that drives human HCC. Another aspect of telomere biology common 
to HCC is the robust activation of telomerase (correlating with increased TERT mRNA 
levels) in nearly 90% of human HCCs. Telomerase re-activation has been suggested to 
promote HCC progression (Piao et al 2004; Kobayashi et al. 2001). Collectively, the current 
data suggest a model wherein telomere shortening drives chromosomal instability and 
cancer-promoting lesions during early stages of hepatocarcinogenesis, whereas 
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chromosomal stability to a level compatible with cancer-cell viability (Farazi and DePinho 
2006) (Figure 2). 
 
Figure 2: Histopathological progression and molecular features of HCC. Continuous cycles of hepatocyte 
destructive–regenerative process foster a chronic liver disease condition that culminates in liver cirrhosis. 
Cirrhosis is characterized by abnormal liver nodule formation surrounded by collagen deposition and scarring 
of the liver. Subsequently, hyperplastic nodules are observed, followed by dysplastic nodules and ultimately 
HCC, which can be further classified into well differentiated, moderately differentiated and poorly 
differentiated tumours, the last of which represents the most malignant form of primary HCC. Telomere 
shortening is a feature of chronic liver disease and cirrhosis. Telomerase reactivation has been associated with 
hepatocarcinogenesis. Loss and/or mutation of p53 and genomic instability also characterize 
hepatocarcinogenesis. p53 loss and/or mutation is shown to occur during progression to HCC, however, there 
is some evidence that loss and mutation of p53 might also occur in the initial stages of hepatocarcinogenesis. 
(From Farazi and DePinho 2006) 
1.3 Signaling pathways and tumor development  
Intact signaling pathways are central to the maintenance and regulation of normal 
functions of cells, tissue and organs, including regulation of cell apoptosis, proliferation, 
migration, invasion and angiogenesis. In the case of signaling pathways that involve 
receptor tyrosine kinases, the activation of the receptor is stimulated by the binding of a 
ligand, such as a growth factor, to the extracellular domain of the receptor. This binding 
causes dimerization of the receptor and activation of an intracellular tyrosine kinase by 
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residues in polypeptides that have downstream effects on apoptosis, cell proliferation, 
migration and invasion, and angiogenesis (Wilhem et al. 2006). 
Many malignancies are caused by a disruption of such signaling pathways, which leads 
to overactivation of downstream regulatory genes. Such overactivation can, in fact, be 
caused by four different mechanisms: overexpression of the growth-factor receptor; 
overexpression of the ligand, which leads to increased activation of the receptor; 
mutations in the receptor tyrosine kinase that result in its constitutive activation, even in 
the absence of ligand binding and receptor dimerization; and lastly, the abnormal 
association of a cellular protein with an intracellular protein tyrosine kinase (Krause and 
Van Etten 2005). 
 





Salis Fabiana, Regulation of amphiregulin gene expression by β-catenin signaling in human 
hepatocarcinoma cells: a novel crosstalk between FGF19 and the EGFR system. Tesi di Dottorato in 
Epidemiologia Molecolare dei Tumori. Universitá degli Studi di Sassari 
29 
The key signal-transduction pathways that have been implicated in hepatocellular 
carcinogenesis include those mediated by VEGF (Vascular Endothelial Growth Factor), 
PDGFR (Platelet-derived Growth Factor Receptors), HGF (Hepatocyte Growth Factor), IGF 
(Insulin-like Growth Factor) and EGFR (Epidermal Growth Factor Receptor), and the 
ras/raf/MAP2K/MAPK, Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways (Figure 
3) (Llovet and Bruix 2008). 
2. Epidermal Growth Factor Receptor (EGFR) 
2.1 Generality 
Human epidermal growth factor receptors (EGFR or HERs), also known as the ErbB 
family of tyrosine kinase receptors and their ligands (EGFR ligands), are important 
regulators of cancer cell growth, angiogenesis and metastasis. 
There are four receptors in the ErbB family: EGFR (HER1 or ErbB1); HER2 (neu or 
ErbB2); HER3 (ErbB3); and HER4 (ErbB4). EGFR, HER2 and HER4 have a tyrosine kinase 
domain, while HER3 lacks the tyrosine kinase domain; thus, HER3 is only able to 
propagate signals in heterodimerization receptor complexes with other HER members 
(Kataoka 2009). 
The receptors have a molecular mass between 170 and 185 kilodalton and are 
composed of a large extracellular ligand-binding domain, which has four subdomains (I–
IV), followed by a transmembrane domain, a small intracellular juxtamembrane domain 
preceding the kinase domain, and a C-terminal tail, on which the docking sites for 
phosphotyrosine-binding effector molecules are found (Citri and Yarden 2006). The 
tyrosine kinase is highly conserved among the different members of the family, except for 
ErbB3, in which key amino acids have been substituted, rendering this receptor devoid of 
tyrosine kinase activity (Normanno and Gullick 2006). In contrast, the extracellular 
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specificity in ligand binding (Olayioye et al. 2000; Yarden 2001; Yarden and Sliwkowski 
2001). 
As shown in Figure 4, ten ligands of EGFR have been reported. These ligands are 
divided into three different categories. The first group includes epidermal growth factor 
(EGF), transforming growth factor α (TGFα), amphiregulin (AR) and Epigen (EPG) which 
bind specifically to the EGFR. The second group includes betacellulin (BTC), heparin-
binding growth factor (HB-EGF) and epiregulin (EPR), which show dual specificity by 
binding both EGFR and ErbB-4. The third group is composed of the neuregulins (NRGs) 
and can be divided in two subgroups based upon their capacity to bind ErbB-3 and ErbB-4 
(NRG-1 and NRG-2) or only ErbB-4 (NRG-3 and NRG-4) (Carraway et al. 1997; Chang et al. 
1997; Harari et al. 1999). None of the EGF family of peptides binds ErbB-2.  
Binding of ligands to the extracellular domain of ErbB receptors induces the formation 
of receptor homo- or heterodimers, and subsequent activation of the intrinsic tyrosine 
kinase domain (Figure 5) (Olayioye et al. 2000), the subsequent autophosphorylation of 
the EGFR createa docking sites for several signaling proteins such as Shc, Grb7, Grb2, Crk, 
phospholipase Cg (PLCg) the kinases Src and PI3K, the protein phosphatases SHP1 and 
SHP2 and the Cbl E3 ubiquitin ligase. Other signaling proteins, such as phospholipase D 
(PLD) and the STAT 1, 3 and 5 proteins, do not bind to the ErbB receptors through the C-
terminal phosphotyrosines, but are also activated upon ligand binding. These interactions 
trigger intracellular signaling cascades such as the ras/raf/MEK/MAPK pathway 
(including the activation of ERK and JUN NH2-terminal kinase-JNK), p38 mitogen- 
activated protein kinase (p38-MAPK), the protein kinase C (PKC) pathway, the PI3K/AKT 
pathway (which can lead to NF-kB activation) and the STAT pathway (Berasain et al. 
2007b). This network is further complicated by several regulatory feedback mechanisms. 
ErbB receptors are activated by binding to growth factors of the EGF-family that are 
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surrounding cells (paracrine secretion) (Figure 5) (Olayioye et al. 2000; Yarden and 
Sliwkowski 2001; Holbro et al. 2003). 
 
Figure 4: EGFR ligands and their binding specificities for human HER family members. (From Cooper et 
al. 2011) 
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ErbB proteins are widely expressed in human and animal tissues, notably in cells of 
epithelial or neuroectodermal origin. Hepatocytes of the mature liver express the highest 
levels of EGFR of any non transformed cell, suggesting an important role for ErbB signaling 
in normal liver function (Dunn et al. 1984). 
2.2 EGFR transactivation 
It has been demonstrated that EGFR activation can be potentiated by the activation of 
other signaling pathway systems. The mechanism by which, a physiological stimulus can 
activate the EGFR without a direct interaction is known as EGFR transactivation. 
Transactivation of the EGFR by ligands of G protein-coupled receptors (GPCRs) is 
perhaps the best characterized example of EGFR activation by heterologous ligands (Ohtsu 
et al. 2006). These include lysophosphatidic acid (LPA), angiotensin II (ANG II), 
endothelin-I, thrombin, IL-8, and prostaglandins such as PGE2. Different mechanisms have 
been proposed to mediate ADAM (A Disintegrin and Metalloproteinase) activation by 
GPCRs.  
These mechanisms can involve the phosphorylation and activation of the ADAMs, and 
are were not completely know, but certainly plays an important role the PKC activation, 
the intracellular fluctuation of Ca2+ and the formation of reactive oxygen species (ROS) 
(Ohtsu et al. 2006). 
The subsequent release of the EGFR transmembrane ligands to the extracellular 
medium leads to the receptor activation (Berasain et al. 2009). 
In addition to GPCRs, the EGFR can be activated by proinflammatory cytokines such as 
interleukin-1b (IL-1b), interferon γ (INTγ) and TNFα, through a metalloproteinase-
dependent release of EGFR ligands (Berasain et al. 2007b; Berasain et al 2009; Pastore et 
al. 2008). TGF-β1 induces a rapid secretion of a member of the EGF family of growth 
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(Murillo et al. 2005). Even the TLRs that are classically activated by pathogen-derived 
ligands and are primarily associated with the innate immune response (chemokine and 
cytokine release), can also be activated as a result of release of malignant cell contents 
(such as the hot shock protein 70 or HSP70), which occurs frequently in progressing 
cancer cells and can activate the ADAMs proteins or the SRC kinase (Shepard et al. 2008). 
2.3 Ligands of the EGF family  
EGFR signaling is stimulated by members of the EGF family of peptide growth factors, 
whose roles in stimulating ErbB receptor signaling and coupling to biological responses 
have been intensively studied (Hynes et al. 2005; Wieduwilt et al. 2008; Riese and Sterne 
1998; Wilson et al. 2009).  
EGFR agonists include the epidermal growth factor (EGF), transforming growth factor-
α (TGFα), heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AR), 
betacellulin (BTC), epiregulin (EPR), and epigen (EPG) (Harris et al. 2003). These agonists 
are expressed as integral membrane proteins and are cleaved by ectodomain (proteolytic) 
shedding such as metalloproteinases to release soluble, mature ligands. These 
metalloproteinases are typically members of the ADAM (a disintegrin and 
metalloproteinase) family of membraneous proteases (Foley et al. 2010). This process 
regulates, for example, bioavailability (and therefore bioactivity) of the ligands and signal 
duration (Massague and Pandiella 1993).  
All the ligands are typically ~55 amino acids in length (Stein and Staros, 2000) and 
share an overall structural homology consisting of a hydrophilic N-terminus (ectodomain) 
containing the EGF-domain, a hydrophobic transmembrane region, a hydrophilic 
cytoplasmic C-terminus called cytoplasmatic tail, and additional motifs like an 
immunoglobulin-like domain, heparin-binding sites and glycosylation sites (Berasain et al. 
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EGF is the only one that has nine EGF domains, but only the one adjacent to the 
membrane binds the EGFR. The EGF domain is characterized by a consensus sequence 
consisting of six spatially conserved cysteine residues (CX7 CX4–5 CX10–13 CXCX8 C) that 
form three intramolecular disulfide bonds that form a motif crucial for binding members 
of the HER receptor tyrosine kinase family (Harris et al. 2003).  
Among these ligands and receptors, TGF-α, AR, HB-EGF, EGFR (HER1) and HER2 play 
crucial roles in cancer cell growth, particularly in stomach, colon, breast and lung cancers, 
as well as melanoma (Miyamoto et al. 2006). No ligands bind to HER2; thus, HER2 has 
been reported to be an orphan receptor and is the preferred co-receptor for dimer 
formation with EGFR, HER3 or HER4, and heterodimers consisting of HER2 and other 
receptors have a greater capacity for translating cell growth signals than homodimers, and 
act synergistically to promote cellular transformation (Graus-Porta et al. 1997). These ten 
EGF ligands bind to EGFR, HER3 and HER4, leading to the formation of heterodimers or 
homodimers, which triggers downstream signal transduction via Ras/ERK, PI3K/AKT or 
STAT (Ono et al. 2006). 
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Amphiregulin (AR) was the third member of the epidermal growth factor (EGF) family 
discovered. It was isolated from the conditioned media of phorbol ester-12-myristate 13-
acetate (PMA) stimulated MCF-7 human breast carcinoma cell (Shoyab et al 1988). AR was 
initially described as a bifunctional regulator of cell growth; it was originally identified as 
a factor capable of inhibiting the growth of certain carcinoma cell lines, while stimulating 
the proliferation of normal cells such as fibroblasts and keratinocytes. Actually, depending 
on its concentration and the nature of the target cell AR promotes the growth of most cell 
types, including normal and transformed cells (Berasain et al. 2007a). 
The human AR gene (geneID 374) spans about 10Kb of genomic DNA and is located on 
the p13-q21 regions of chromosome 4. It is composed of six exons, encoding a 1.4kb pre-
protein mRNA transcript. The exons vary in size from 112 to 270bp and are interrupted by 
introns ranging from 1.25 to 2.1kb (Figure 7) (Plowman et al. 1990). 
Figure 7: Human AR gene showing the exon organization and protein domains. (Plowman et al. 1990). 
The AR protein is synthesized as a 252 amino acid transmembrane glycoprotein, also 
known as transmembrane precursor or pro-form (pro-AR) (Figure 8). Sequence analysis 
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several other semi-conserved residues that form disulfide bridges giving rise to a three-
looped structure, which is involved in binding to the EGFR (Plowman et al. 1990). Besides 
EGF, this so called EGF domain is shared by other members of the EGF family (Tzhar and 
Yarden 1998; Harris et al. 2003; Sanderson et al. 2006; Lee et al. 2003c). Outside this EGF-
like region these precursors show little sequence homology, yet AR also has an N-terminal 
extension of 43 amino acids containing glycosylation sites and composed mainly of very 
basic, hydrophilic residues that are thought to confer heparin-binding properties, and a 
similar heparin-binding domain is also present in HB-EGF (Higashiyama et al. 1992). 
Interestingly, the N-terminal extension of pro-AR also contains two consecutive Lys-Arg-
Arg-Arg motifs resembling nuclear targeting signals, which may account for its reported 
association with the nucleus (Modrell et al. 1992). AR precursor (pro-AR), like other 
growth factors members of the EGF family, share an overall structural homology 
consisting of a hydrophilic N-terminus (ectodomain) containing the EGF-domain, a 
hydrophobic transmembrane region and a hydrophilic cytoplasmic C-terminus 
(cytoplasmatic tail) (Figure 8) (Berasain et al. 2007a). The cytoplasmatic tail of HB-EGF 
can traslocate from the cell surface to the inner nuclear membrane (INM) where it 
promotes cell cycle progression (Higashiyana et al. 1991). Recent work shows that the 
cytoplasmatic tail of AR participates in the regulation of autocrine growth and 
differentiation of keratinocytes (Stoll et al. 2010). Other works have demonstrated that the 
proAR translocation into the INM and interaction with lamin A, results in the induction of 
heterochromatinization and global transcriptional suppression (Isokane et al. 2008).  
At the plasma membrane AR precursor is subjected to sequential proteolitic cleavage to 
release the mature soluble factor in a process known as ‘‘ectodomain shedding’’.  
Depending on the cell type and microenvironment, AR can be produced in multiple cellular 
and mature forms using alternative pro-AR cleavage sites and glycosylation motifs, thus 
impacting the biological activity of AR (Busser et al. 2011). Pro-AR cleavage at two N-
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amino acids (of ~19 and ~21kDa), alternatively pro-AR cleavage can produce a larger 
43kDa soluble protein corresponding to the entire extracellular domain. Additionally a 
9kDa soluble form composed almost exclusively of the EGF-like domain has been also 
observed (Brown et al. 1998, Shoyab et al. 1988) (Figure 9).  
 
Figure 8: Structure and cellular processing of pro-amphiregulin. (Adaptation of Berasain et al. 2007a) 
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The proteolytic reaction is mediated mainly by membrane-anchored metalloproteases 
of the ADAM family (a disintegrin and metalloprotease) (Blobel 2005; Ohtsu et al. 2006). 
Various members of the ADAM family have been implicated in EGFR ligand cleavage, 
including ADAM 9, 10, 12, 15, 17, and 19 (Ohtsu et al. 2006). However, ADAM17 (ADAM 
metallopeptidase domain 17), which is also known as tumour necrosis factor-α (TNF-α)-
converting enzyme, or TACE, together with ADAM10, are thought to play a central role 
(Blobel 2005). ADAM17 can cleave the AR, EREG, TGF-α, and HB-EGF membrane anchored 
precursors, while ADAM 10 is a key sheddase for EGF, BTC, and can also cleave the HB-
HGF transmembrane precursor (Berasain et al. 2009). 
The proteolytic activity of ADAMs is therefore crucial for the generation of soluble 
EGFR ligands and receptor activation. Importantly, the proteolytic activity of ADAMs is in 
turn subject to regulation by multiple upstream signals, which adds another layer of 
complexity to the system. In fact, there is a growing list of physiological stimuli that can 
trigger EGFR signaling through the stimulation of ligand shedding, a process known as 
EGFR transactivation (Ohtsu et al. 2006; Fisher et al. 2003). Transactivation of the EGFR 
by ligands of G protein-coupled receptors (GPCRs) is perhaps the best characterized 
example of EGFR activation by heterologous ligands (Berasain et al. 2009). 
2.4.2 Functions of the Amphiregulin 
As previously mentioned, historically, this growth factor was named Amphiregulin 
because it can either induce proliferation and differentiation of fibroblasts in culture or 
can inhibit the growth of normal epithelial cells and aggressive carcinoma cell lines 
(Shoyab et al. 1988). In humans AR is constitutive expressed in the normal ovary, testis, 
and breast tissue, but can also be detected in the placenta, pancreas, heart, colon, lungs, 
spleen, and kidneys and may be involved in early development or in processes as diverse 
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The physiological role of AR seems to be related to the development of the mammary 
epithelium (Luetteke et al. 1999; Sternlicht et al. 2005) and with a mitogenic and 
hepatoprotective effects (Berasain et al. 2005a; Berasain et al. 2005b). 
On one side the expression of AR is induced in chronic experimental liver damage and 
in human liver cirrhosis and is readily detected in rodent liver after partial hepatectomy 
(Berasain et al. 2005a), participating in the proliferative responses of the hepatocyte. On 
the other hand, the AR has a hepatoprotective function in different mouse models of acute 
injury, such as carbon tetrachloride (CCl4) administration or Fas receptor activation 
(Berasain et al. 2005b). 
The role played by AR in hepatocyte proliferation and cytoprotection seems to be 
unique because studies in AR knockout mice showed that the effects exerted by AR on 
liver parenchymal cells could not be compensated by other EGFR ligands, such as TGF-α 
and HB-EGF, also induced during liver (Berasain et al. 2005b; Berasain et al. 2005a). 
2.4.3 AR and EGFR system in the HCC 
The EGFR system is considered as an important defense mechanism for the liver during 
acute tissue injury, however, its chronic stimulation can participate in the neoplastic 
conversion of the liver (Berasain et al. 2007b). The receptors EGFR/ErbB-1 (Nakopoulou 
et al. 1994; Kira et al. 1997; Ito et al. 2001b), neu/Her2/ ErbB-2 (Nakopoulou et al. 1994; 
Ito et al. 2001b), Her3/ErbB-3 (Ito et al. 2001b) and Her4/ErbB-4 (Ito et al. 2001b) are 
expressed in HCCs; however, staining frequency and intensity of the tumor tissues in 
comparison to the surrounding non-tumorous liver tissues differ between these studies. It 
is noteworthy that in contrast to other carcinomas (e.g. breast cancer), amplification of the 
ErbB2 gene is considered uncommon in human HCCs (Xian et al. 2005). 
Overexpression of AR, TGF-α, BTC and HB-EGF has been observed in liver cirrhosis and 
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acute and chronic liver injury. These factors together with ADAM17 overexpression are 
believed to contribute to EGFR activation during hepatocarcinogenesis (Berasain et al. 
2007b; Berasain et al. 2005a; Schiffer et al. 2005). These findings suggest an enhanced 
availability of soluble AR from the early stages of hepatocarcinogenesis (Castillo et al. 
2006). Interestingly, were observed that AR was able to stimulate its own gene expression 
in hepatocellular carcinoma cells through the activation of the EGFR, suggesting the 
existence of a positive feedback loop for AR production (Castillo et al. 2006). A similar 
response has been reported in other tumor cell types, such as colon cancer cells, where AR 
expression is induced by the EGFR ligand TGF-α in conjunction with the cyclooxygenase-2-
derived prostaglandin E2 (Shao et al. 2003). AR was constitutively expressed and released 
to the CM of hepatocellular carcinoma cells, on which it exerted promitogenic and 
antiapoptotic effects through the activation of the EGFR (Castillo et al. 2006). 
Depending on the cellular context, AR can promote such diverse effects as self-
sufficiency in growth signals, tissue invasion, and evasion of apoptosis, processes all 
involved in tumor development and progression (Hanahan and Weinberg 2011). AR gene 
overexpression has been demonstrated in a wide variety of human cancer tissues. 
However, the genetic or epigenetic alterations responsible for this overexpression remain 
unknown despite numerous identified stimuli. 
AR stimulates cell growth and the apoptosis resistance as well as allowing the cancer 
cells growth under non adhesive conditions. All these characteristics were lost when gene 
AR expression was silencied in a specific manner (Castillo et al. 2006). Stably transfected 
HCC cell clones that overexpress AR show an increase in growth rate, greater capacity to 
growth in absence of substrate and increase aggressiveness and tumorigenic potential 
when injected in nude mice (Castillo et al. 2006).  
Crosstalk between the Insuline-like growth factor (IGF) pathway and ErbB1 has also 
been demonstrated in various cellular backgrounds by showing that activation of IGF-1 
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HB-EGF (Adams et al. 2004, Berasain et al. 2007b) and the proliferative effect of IGF-2 in 
human HCC cell lines requires the EGFR activation through the autocrine/paracrine 
liberation of the AR (Desbois-Mouthon et al. 2006). 
Recent evidence indicates that cyclooxygenase-2 (COX-2) and EGFR are involved in 
hepatocarcinogenesis. The transactivation of the EGFR was induced by the prostaglandin 
E2 (PGE2) in human HCC cell line through the activation of the tyrosin kinase c-Src (Han et 
al. 2006). It has also been demonstrated that PGE2 induces the expression of AR in in vitro 
cultures of hepatocytes (Berasain et al. 2005a), while EGF can induce COX-2 expression in 
human HCC cells (Han et al. 2006). 
3. β-catenin 
3.1 Generality 
β-catenin is an archetypal member of the armadillo repeat protein family, which 
includes α-catenin, β-catenin and γ-catenin. β-catenin was the first identified and it plays 
an integral role in establishing adherents junctions by directly interacting with cadherin 
(McCrea et al. 1991). It is also a critical transcriptional coactivator in the canonical Wnt 
signaling pathway that controls cell fate and proliferation when it forms a complex with 
members of Tcf/LEF-1 transcription factors in the nucleus (Graham et al. 2000). 
As β-catenin is involved in various protein–protein interactions that are crucial for 
embryogenesis, development and tumorigenesis, its protein levels are tightly regulated by 
a dedicated degradation mechanism (Angers and Moon 2009). In the cadherin–catenin cell 
adhesion complex, β-catenin can simultaneously interact with cadherin, a cell adhesion 
molecule, and α-catenin, an actin-binding protein. The formation of a cadherin/β-
catenin/α-catenin ternary complex is essential for linking cadherin-mediated cell–cell 
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The human β-catenin gene (CTNNB1) is located on chromosome 3p21. The size of the 
gene is 23.2kb, containing 16 exons (Nollet et al. 1996). The primary sequence of β-catenin 
is highly conserved from insects to humans, and its critical biological role in vertebrates is 
especially highlighted by strict conservation (>95% sequence identity) of a 781 residue 
sequence. The molecular weight of the β-catenin protein is of 92KDa. The overall structure 
of β-catenin consists of three distinct domains, an N-terminal tail of approximately 130 
amino acids containing the α-catenin-binding site, a central arm domain of 550 amino 
acids that binds to the cytoplasmic region of cadherin and a C-terminal tail of 100 amino 
acids (Figure 10) (Shapiro and Weis 2009; Akiyama 2000; Nuse and Willert 1998). The N-
terminal region contains consensus phosphorylation sites for GSK3β, while the C-terminal 
region possesses the transactivator function required for activation of target genes. The 
central region contains 12 imperfect sequence repeats of 42 amino acids known as 
armadillo repeats, which are sequentially packed together through hydrophobic interfaces 
into a superhelical structure (Huber et al. 1997) (Figure 10). The individual armadillo 
repeats consist of three α-helices that are connected by short loops and which are 
required for the interaction with various proteins, including cadherins, APC and TCF/LEF 
(Akiyama 2000). 
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3.2 The Wnt/β-catenin signaling 
The term ‘‘Wnt’’ was introduced 20 years ago fusing the names of two orthologous 
genes: Wingless (Wg), a Drosophila segment polarity gene, and Int-1, a mouse 
protooncogene (Giles et al. 2006). Wnt signaling is involved in various aspects of 
embryogenesis and development, including cell proliferation, differentiation, migration, 
cell polarity, cell-to-cell communication, and survival (Li et al. 2006; Moon et al. 1997; 
Miller et al. 1999). As a result, mutations in the Wnt pathway are often linked to human 
birth defects, cancer and other diseases (Clevers 2006). 
The 19 proteins of the Wnt family are small, secreted glycoproteins that are highly 
conserved in a wide variety of organisms, from “Caenorhabditis elegans” to humans, 
suggesting a critical role for Wnt signaling in cell fate (Miller et al. 1999, Moon et al. 2002, 
Schneider et al. 2003). Wnt proteins signal through two types of receptors: seven-pass 
transmembrane receptors known as Frizzled proteins (Fz), and the single-pass 
transmembrane co-receptors lipoprotein- receptor related proteins (LRPs) (Huang et al. 
2004). 
Wnt ligands are classified into two distinct groups based on the subcellular signaling 
elements. The first group, referred to as the Wnt1 group, predominantly uses the 
“canonical” pathway for intracellular signaling and includes Wnt1, Wnt2a, Wnt3a, and 
Wnt8 (Figure 11). The second group, the Wnt5a group, includes Wnt4, Wnt5a, and Wnt11 
and uses a very different subcellular signaling network, the “non canonical” pathway 
(Figure 12). 
In the canonical pathway, in the absence of Wnt proteins, cytoplasmic β-catenin protein 
is constantly degraded by the action of the Axin complex, which is composed of the 
scaffolding protein Axin, the tumor suppressor adenomatous polyposis coli gene product 
(APC), casein kinase 1 (CK1), and glycogen synthase kinase 3 (GSK3β). CK1 and GSK3β 
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45 and the second in the threonine 41 and serine 37 and 33), resulting in β-catenin 
recognition by β-Trcp, an E3 ubiquitin ligase subunit, and subsequent β-catenin 
ubiquitination and proteasomal degradation (He et al. 2004). This continual elimination of 
β-catenin prevents β-catenin from reaching the nucleus, and Wnt target genes are thereby 
repressed by the DNA-bound T cell factor/lymphoid enhancer factor (TCF/LEF) family of 
proteins. The Wnt/β-catenin pathway is activated when a Wnt ligand, such as Wnt1, Wnt2, 
Wnt3, Wnt3a, and Wnt8, binds to a seven-pass transmembrane Frizzled (Fz) receptor and 
its co-receptor, low-density lipoprotein receptor related protein 6 (LRP6) or its close 
relative LRP5. The formation of a likely Wnt-Fz-LRP6 complex together with the 
recruitment of the scaffolding protein Dishevelled (Dsh) results in LRP6 phosphorylation 
and activation and the recruitment of the Axin complex to the receptors. These events lead 
to inhibition of Axin-mediated β-catenin phosphorylation and thereby to the stabilization 
of β-catenin, which accumulates and travels to the nucleus to form complexes with 
TCF/LEF and activates Wnt target gene expression (Figure 11) (Emami et Corey 2007). 
These Wnt/β-catenin targets include gene products responsible for proliferation (MYC, 
MYB, C-JUN, Cyclin D1), antiapoptosis (survivin), invasion (matrix metalloproteinases 
(MMPs) and angiogenesis (VEGF). Thus, the activation of Wnt targets not only regulates 
tissue development and regeneration but it can also influence tumor growth and 
progression in the case of aberrant nuclear accumulation of β-catenin (Breuhahn et al. 
2006). 
In the ‘‘non-canonical’’ Wnt pathway, Wnts proteins such as Wnt4, Wnt5a, Wnt5b, 
Wnt6, Wnt7a, and Wnt11 bind to FZ, but transduction of the signal does not require β-
catenin (Kuhl et al. 2000). The activation of the FZ receptor and co receptors such as Ror2 
and Ryk and transduction proceeds through diverse mechanisms dependent on either the 
Dishevelled (Dsh) downstream effector or Ca2+. Dsh can be activated by FZ directly or 
through the induction of heterodimeric G-proteins. Dsh has been shown to activate the 
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cytoskeleton. Another downstream effector of Dsh is JNK which can be activated by RhoA 
to regulate PCP (planar cell polarity) during eye development. Signal transduction through 
Ca2+ activates nemo-like kinase (NLK) and the nuclear factor of activated T cells (NFAT) 
with NLK inhibiting canonical Wnt signalling through the phosphorylation of TCF/LEF 
(Veeman et al. 2003a; Veeman et al. 2003b) (Figure 12). 
 
Figure 11: Wnt/β-catenin signaling. (From Flaherty and Dawn 2008) 
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Several extracellular secreted factors regulate Wnt signaling. Secreted Frizzled-related 
proteins (SFRP), Wnt inhibitory factor-1 (WIF-1) and Cerberus sequester Wnts and 
prevent their association with the FZ receptors (Suzuki et al. 2005) and therefore inhibit 
the canonical and non-canonical Wnt pathways (Logan amd Nusse 2004). Dickkopf 
proteins (DKKs), which belong to a multigene family, are another type of inhibitor of Wnt 
pathways (Zorn et al. 2001). DKKs inhibit Wnt signaling by binding to and antagonizing 
LRP5/6 receptors and promoting their internalization to lysosomes (Levasseur et al. 
2005; Davidson et al. 2002). 
3.3 Wnt/β-catenin signaling in HCC 
Mutations affecting the Wnt/β-catenin pathway appear to be the most frequent genetic 
event in human HCC (Laurent-Puig and Zucman-Rossi 2006). Interestingly, recent data 
showed that the Wnt/β-catenin signaling pathway exerts a critical role in many aspects of 
liver development and physiology (Ober et al. 2006; Tan et al. 2008; Decaens et al. 2008; 
Benhamouche et al. 2006). It is tightly controlled by multiple factors, and understanding 
such regulation opens a unique field for the development of targeted treatments. 
Various molecular and genetic factors participate to such aberrant activation of the 
Wnt/β-catenin pathway. Firstly, mutations are frequently identified in genes encoding for 
the main actors of the pathway. Gain-of-function mutations of CTNNB1 (encoding for β-
catenin) are encountered in about one third of HCCs (de La Coste et al. 1998) and define 
CTNNB1 as the most frequently mutated gene in HCCs. Conversely, loss-of-function 
mutations of negative regulators of the pathway are also observed, namely mutations of 
the AXIN1 and AXIN2 genes (<5%) and of the APC gene (exceptional) (Laurent-Puig and 
Zucman-Rossi 2006). The activation of the Wnt/β-catenin signalling pathway is mainly 
attributed to the mutations of the APC gene in colon cancer (Cottrell et al. 1992). However, 
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in APC inactivation (Lee et al. 2003b; Yang et al. 2003). Beside such mutational events, the 
Wnt/β-catenin pathway can be also activated in HCCs as a consequence of a deregulated 
dialogue between the tumor cells and their microenvironment. For instance, an autocrine 
Wnt stimulation loop can be established following epigenetic events that change the 
expression profiles of the ligands, the extracellular inhibitors and the receptors of the Wnt 
family (Bengochea et al. 2008). A modified crosstalk with other signaling pathways such as 
HGF or TGF-β can also account for the aberrant activation of the Wnt/β-catenin pathway 
in HCCs (Hoshida et al. 2009; Monga et al. 2002). 
Mutations in each of the components of the complex may cause abnormal cytosolic 
stabilization of β-catenin, mutations of the β-catenin gene itself appear to be the most 
common cause for stabilization in pathological situations. These mutations usually affect 
residues at position 33 (Ser), 37 (Ser), 41 (Thr) or 45 (Ser) located in exon 3 of the human 
β-catenin gene that are the targets of priming phosphorylation by CKIα (Ser45) or 
subsequent phosphorylation by GSK3β (Ser33, Ser37 and Ser41) (De La Coste et al. 1998; 
Hsu et al. 2000; Satoh et al. 2000; Wong et al. 2001). Moreover, β-catenin mutations and 
exon 3 deletions have been identified in 48% of sporadic hepatoblastomas, a type of 
childhood malignant liver tumor (Koch et al. 1999). The above results strongly suggest 
that the APC/β-catenin pathway is an important player in liver tumorigenesis. 
Activation of β-catenin finally leads to the transcriptional activation of a variety of 
genes (Lee et al. 2007). However, not much is known about the role of specific genes 
activated with regard to their role in tumor development. On the other hand, glutamine 
synthetase (GS), one of the enzymes identified to be regulated by nuclear β-catenin, may 
be a candidate that contributes to enhanced malignancy of HCCs (Cadoret et al. 2002; 
Loeppen et al. 2002). In fact, Osada et al. demonstrated that GS expression may enhance 
the metastatic potential in HCC, and that GS immunostaining identifies HCC patients with a 
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intact liver, GS is confined to a small population of hepatocytes located around the hepatic 
terminal venules and is regulated in a highly complex manner (Gebhardt et al. 2007). 
Deregulated expression of β-catenin, which may result from APC defects, activating 
mutations in the β-catenin gene itself, or other alterations in the Wnt pathway, has been 
implicated as an important step in carcinogenesis. β-catenin immunostaining showed 
increased membranous and cytoplasmic expression in most HCCs by comparison with non 
tumoral hepatocytes (Ihara et al. 1996). More importantly, abnormal nuclear localization 
of β-catenin was revealed in a 43% of HCCs. There is a strong correlation between nuclear 
β-catenin staining and somatic mutations of the β-catenin gene in HCC, indicating that 
activation of the Wnt/β-catenin pathway in HCC occurs predominantly through activating 
mutations in the β-catenin gene itself. It differs from colorectal cancers, in which APC 
mutations are responsible for β-catenin stabilization in 80% of the cases (Rubinfeld et al. 
1996), and from melanoma or ovarian and uterine carcinomas, in which very occasional 
mutations can be found despite frequent β-catenin overexpression (Palacios et al. 1998; 
Fukuchi et al. 1998; Rimm et al. 1999). 
β-catenin mutations and interstitial deletions have been reported in both primary HCC 
and hepatoma cell lines (Miyoshi et al. 1998; De La Coste et al. 1998). Once again, the 
alterations affect putative phosphorylation residues in the regulatory site, but Ser37 was 
rarely mutated in HCC. Fifty percent of HCCs that develop in transgenic mice expressing c-
myc or H-ras in the liver contain β-catenin mutations, suggesting that β-catenin activation 
can cooperate with ras or myc in HCC progression (De La Coste et al. 1998). Previously it 
has been shown that β-catenin gene mutation and nuclear accumulation of the protein in 
HCCs ranged from 13 to 34% and from 11 to 43% respectively (De La Coste et al. 1998; 
Hsu et al. 2000; Taniguchi et al. 2002; Wong et al. 2001). HCV-associated HCCs tend to 
have higher frequencies of both β-catenin mutations and nuclear accumulation than HBV-
associated ones. In addition, mutation of Axin1 has been found in approximately 5–10% of 
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frequently observed at the N-terminal half of the protein, which might stabilize β-catenin 
by impeding the formation of the APC/GSK3β/β-catenin complex (Satoh et al. 2000; 
Taniguchi et al. 2002). Besides Axin and β-catenin mutations, inappropriate activation of 
the Wnt/β-catenin signalling pathway can be brought about when the upstream mediators 
are dysregulated. Overexpression of the Wnt ligand and the Frizzled receptor has been 
demonstrated in human HCC. On the other hand, the Wnt antagonist, sFRP1 has been 
found to be epigenetically silenced in human cancers including HCC (Suzuki et al. 2002). 
Likewise, a recent study has shown that Dsh-1 and Dsh-3 are overexpressed in human HCC 
(Chan et al. 2006). Overexpression of Dsh is associated with β-catenin accumulation and 
Wnt/β-catenin signalling activation (Uematsu et al. 2003a; Uematsu et al. 2003b). In 
addition, it has been recently demonstrated that two Dsh inhibitors, HDPR1 and Prickle-1, 
are also frequently underexpressed in human HCC (Chan et al. 2006; Yau et al. 2005). PIN1 
is another Wnt signalling regulator found to be dysregulated in HCC. Overexpression of 
PIN1 stabilizes β-catenin by inhibiting its interaction with APC (Ryo et al. 2001). 
Interestingly, overexpression of PIN1 and mutation of β-catenin appear to be mutually 
exclusive events in Wnt signalling activation in HCC (Pang et al. 2004). Apart from the 
above-mentioned genes, other members of the Wnt/β-catenin signalling pathway, such as 
LPR5/6 and their antagonists DKK1/3, are also subjects of investigation (Niehrs 2006). It 
would not be surprising that more Wnt/β-catenin regulators would be identified and 
implicated in carcinogenesis (Liao and Lo 2008). 
4. Crosstalk between Wnt/β-catenin and EGFR system in cancer. 
Cancer development is a complex progress in which many signaling pathways are 
involved. Cross-communication between different pathways allows the integration of the 
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tumorigenesis, but how they crosstalk and co-activate tumor progression remains an 
unanswered, interesting topic. 
Crosstalk between Wnt and EGFR has been identified in some tumors. In breast 
cancers, Wnt overexpression activates signaling via EGFR (Faivre and Lauge 2007; 
Musgrove 2004). In HC11 mammary epithelial cells, constitutive expression of Wnt1 and 
Wnt5a accompanies activation of EGFR and MAPK. Inhibition of EGFR kinase activity and 
addition of sFRP1 both prevent this effect. TGFα and other EGFR ligands are not induced 
by Wnt-1 or Wnt-5a, but addition of metalloproteinase inhibitors blocks the stimulation of 
EGFR and ERK phosphorylation. Thus, Wnt activation of EGFR is apparently mediated by 
an increase in the availability of EGFR ligands (Civenni et al. 2003). Further studies 
showed that in breast cancers, Wnt1 transactivates EGFR, implying that constitutive Wnt 
signaling might impact not only the canonical pathway but also EGFR activity by 
augmenting ligand availability (Schlange et al. 2007). In liver-specific non-mutated β-
catenin-overexpressing transgenic mice, EGFR seems to be a direct target of the activated 
Wnt signaling pathway, and EGFR activation might contribute to some mitogenic effect of 
increased β-catenin in the liver (Tan et al. 2005). In NSCLC, there is a positive correlation 
between activated EGFR mutation and nuclear accumulation of β-catenin (Suzuki et al. 
2007). All of these results suggest a close correlation between Wnt and EGFR signal 
pathways in cancers. 
Many studies indicate that Wnt and EGFR signaling crosstalk via receptor tyrosine 
kinase pathways. EGFR mediated PI3K/AKT activation promotes β-catenin transactivation 
and tumor cell invasion, suggesting that EGFR activation transactivate β-catenin activity 
via receptor tyrosine kinase pathways in tumor cells (Lu et al. 2003; Ji et al. 2009; Sharma 
et al. 2002; Agarwal et al. 2005). In breast cancers, upregulation of Wnt-1 induces EGFR 
and Erk1/2 MAPK activation (Faivre et al. 2007). In APC deficient mice, Wnt activity 
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The crosstalks between Wnt and EGFR are summarized in Figure 13. Both Wnt and 
EGFR signaling are closely related with tumorigenesis. In recent years a considerable body 
of evidence shows that Wnt and EGFR crosstalk with each other in cancer development. 
Addition of Wnt ligands transactivates EGFR signaling, possibly through Frizzled and its 
downstream partners. EGFR can form a complex with β-catenin and further activate Wnt 
pathway. In cancers, mutations or dysregulation in the Wnt pathway often induce EGFR 
activation. This review also points out several possible convergence points between Wnt 
and EGFR signaling, such as Frizzled, β-catenin and NKD2. Tight regulation of those 
proteins maintains the homeostasis and prevents from tumorigenesis. Further studies will 
surely disclose more convergence points between Wnt and EGFR signaling. Mutations in 
key proteins of Wnt and EGFR pathways have been found in most of the cancers. 80% of 
colon cancers have APC mutations (Powel et al. 1992) and 50-70% of breast, colon and 
lung cancers have EGFR and ErbB3 mutations (Normanno et al. 2003). However, what 
percentage of conincidence of mutations in both EGFR and Wnt pathways in those 
patients, remain a very important and interesting topic. 
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5. Fibroblast growth factor (FGF)/FGF receptor (FGFR) system 
5.1 Generality 
The fibroblast growth factor (FGF) family consists of 22 structurally related proteins 
(FGF1 to FGF14, FGF16 to FGF23) that are involved in various biological processes 
including embryonic development, wound healing, angiogenesis and metabolic signaling 
(Ornitz and Itoh 2001; Itoh and Ornitz 2004; Popovici et al. 2005; Beenken and 
Mohammadi 2009). Many of the FGFs are secreted proteins involved in paracrine cell 
signaling. Because these FGFs display high affinity for heparin sulfate proteoglycans in the 
extracellular matrix of tissues, their signaling tends to remain spatially near their site of 
release. 
Most of these signaling molecules bind to and activate members of the FGF receptor 
(FGFR) family. The FGFR family is composed of four receptor tyrosine kinase designated 
FGFR1-4 and one receptor which lacks a cytoplasmatic tyrosine kinase receptors domain, 
designated FGFR5. Within the FGFR family, FGFR4 is the dominant isoform expressed in 
mature hepatocytes and is expressed at higher levels in the liver compared to other organs 
(Lin and Desnoyers 2012). 
FGF signaling is activated by a ligand-receptor interaction that results in the 
autophosphorylation of tyrosine residues in the intracellular region of an FGFR. The signal 
is further relayed through four distinct pathways: the Janus kinase/signal transducer and 
activator of transcription (Jak/Stat) (Hart et al. 2000; Deo et al. 2002; Udayakumar et al. 
2002), phosphoinositide phospholipase Cγ (PLCγ) (Burgess et al 1990; Mohammadi et al 
1991), PI3K (Hart et al. 2001) and Erk pathways (Hadari et al. 2001; Dailey et al. 2005) 
(Figure 14). The formation of a complex between FGFR, fibroblast growth factor receptor 
substrate 2 (Frs2a), Src homology region 2 domain containing phosphatase 2 (Shp2) and 
growth factor receptor-bound protein 2 (Grb2) facilitates son of sevenless homology 
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activation via Grb2-associated binding protein 1 (Gab1). FGF signaling is tightly regulated 
and modulated at multiple levels, both intracellularly and extracellularly. For example, the 
bioavailability of secreted FGF ligands is regulated by their binding to extracellular 
heparan sulfate proteoglycans (HSPGs). HSPGs also act as important co-receptors for FGF 
ligands by facilitating the assembly of activated ligandreceptor complexes (Ornitz and Itoh 
2001). Intracellularly, the FGF signaling cascade is further regulated by negative-feedback 
mechanisms at multiple levels by dual specificity phosphatases (DUSPs), similar 
expression to FGF (Sef), Spred and Sprouty proteins (Dailey et al. 2005). Several of these 
inhibitors are themselves downstream transcriptional targets of the FGF pathway. 
FGFs range in molecular weight from 17 to 34KDa in vertebrates; all members share a 
conserved sequence of 120 amino acids that show 16-65% sequence identity (Ornitz and 
Itoh 2001). The FGFs gene is located on chromosome 11q13.3 and the size complete gene 
is 6.10kb, containing 3 exons. 
Within the family of FGFs there are seven subfamilies consisting of FGFs that display 
increased structural and functional similarity. These subfamilies can also be classified into 
three groups: the intracellular FGF11/12/13/14 subfamily also known as FGF homology 
factors that do not signal through the FGFRs; the hormone-like (endocrine) subfamily also 
known as FGF19 subfamily that comprise the human FGF19/21/23 and the mouse fgf15 
proteins that have a reduced affinity for heparin sulfate proteoglycan and contain 
intramolecular disulfide bonds, which may function to increase their stability in plasma 
and allow them to function as hormones (Harmer et al. 2004), and the canonical FGF 
subfamily comprising the FGF1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18 and 
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Figure 14: The FGF-FGFR signaling pathway. (Adapted from Lanner and Rossant 2010) 
 
Figure 15: FGFR structure. (From Mason 2008) 
The prototypical FGFR is composed by an extracellular region containing three 
immunoglobulin (Ig)-like domains (D1-D3), a single transmembrane helix and a 
cytoplasmatic domain with protein tyrosine kinase activity. A unique hallmark of FGRs is 
the presence of a contiguous stretch of acidic residues in the linker between D1 and D2 
which is termed “acid box” (AB) (Mohammmadi et al. 2005). Ligand binding requires both 
D2 and D3 domains. The D1 domain and the D1-D2 linker are dispensible for ligand 
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can generate a range of FGFR1–4 isoforms, some of which are secreted proteins. Most 
significantly, alternative splicing within the region encoding the C-terminal part of the 
third extracellular immunoglobulin loop in FGFR1–3 generates IIIb or IIIc isoforms, 
dramatically affecting ligand–receptor binding specificity (Mason 2007). The D3 
alternative splicing event elaborates the number of principal FGFRs from four to seven: 
FGFR1b, FGFR1c, FGFR2b, FGFR2c, FGFR3b, FGFR3c, FGFR4 (Figure 15). 
5.2 FGF19/FGFR4 signaling 
FGF19 was cloned by homology to its mouse ortholog fgf15 (Iwata et al. 2009, 
Nishimura et al. 1999). The FGF19 gene is located on human chromosome 11q13 and 
belongs to an evolutionary conserved cluster of genes that includes FGF3, FGF4 and Cyclin 
D1 (Wu et al. 2010). The full-length cDNA encodes a 216 amino acid protein containing an 
amino-terminal signal sequence, two highly conserved cysteine residues and a clear 
relationship to other members of the FGF family. FGF19 mRNA is found in brain, skin, 
cartilage, retina, gall bladder, small intestine, kidney, placenta and umbilical cord 
(Nishimura et al. 1999; Xie et al. 1999).  
As mentioned before most FGFs function primarily in a paracrine and/or autocrine 
fashion. However the FGF19 subfamily members can function as endocrine factors or 
hormones. FGF19 can act as a classic endocrine hormone to regulate bile acid homeostasis 
as well as glucose and lipid metabolism. In the liver, FGF19 is able to suppress bile acid 
production by downregulating the key enzyme in bile acid biosynthesis (Pai et al. 2008). In 
adipose tissue it may increase glucose uptake by regulating a glucose transporter. A 
deregulating FGF19 signaling may be critical for development and progression of a 
numbers of cancers, because it can contribute to cell proliferation, survival, invasion, 
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The effects of FGF19 on downstream signaling MAPK and β-catenin pathways are 
mediated by its cognate receptor FGFR4. Unlike the other members of the FGF family, 
FGF19 binds only the FGFR4 that is the most widely distributed member of the FGFR 
family. Under normal circumstances, FGFR4 is expressed in liver, lung, gall bladder, small 
intestine, pancreas, colorectal, lymphoid, ovary and breast tissue (Lin et al. 2007). 
Typically the binding interaction requires stabilization by heparin sulfate 
glycosaminoglycan cofactors that are present in the extracellular matrix (HS) (Ornitz and 
Ithoh 2001; Beenken and Mohammadi 2009; Asada et al. 2009). The interaction with HS 
also limits the diffusion of FGFs from their site of release and creates a low-affinity FGF 
reservoir that enhances paracrine signaling (Beenken and Mohammadi 2009; Asada et al. 
2009). In contrast the FGF19 subfamily members have reduced affinity for HS which 
increases the radius of diffusion and enables endocrine signaling. FGF19 can bind FGFR4 
in the presence of a coreceptor belonging to the Klotho family (Wu et al. 2007) that 
comprised Klotho (KL) and β-Klotho (KLB). The Klotho proteins are type I transmembrane 
glycoproteins containing extracellular regions that contain two beta-glycosidase-like 
repeats with restricted tissue distribution (Kurosu and Koro-o 2009). KLB is the 
coreceptor of FGFR4, is required for the activity of FGF19 (Kurosu et al. 2007; Lin et al. 
2007). KLB is a 130kDa trans-membrane protein with a short (29 amino acids) 
intracellular domain that has no predicted kinase activity and two extracellular 
glycosidase domains that lack a characteristic glutamic acid residue essential for 
enzymatic activity. KLB exhibits a more restricted expression profile in adipose, liver and 
pancreas tissues (Lin et al. 2007). KLB and FGFR4 are both expressed at high levels in 
mature hepatocytes (Lin et al. 2007), where KLB stabilizes FGF19-FGFR4 binding to 
regulate the expression of cholesterol 7a-hydroxylase (CYP7A1) and hepatocyte 
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5.3 FGF19/FGFR4 in cancer. 
The FGF19/FGFR4 signaling axis promotes hepatocyte proliferation and is involved in 
several human cancers, in particular HCC. High expression levels of FGF19 were detected 
in several human tumors including colon adenocarcinoma, lung squamous cell carcinoma 
and hepatocellular carcinoma. FGF19 activates several signaling events in the liver that 
might contribute to tumorigenesis. Besides the MAPK pathway, it is known that the Wnt 
pathway crosstalks with FGF signaling (Pai et al. 2008) and 44% of neoplastic hepatocytes 
in FGF19 transgenic mice have nuclear staining for β-catenin (Nicholes et al. 2002) (Figure 
16). FGF19 increase tyrosine phosphorylation of β-catenin within the E-cadherin- β-
catenin-α-catenin complex, and induces loss of E-cadherin binding to β-catenin in colon 
cancer cell lines, potentially contributing to tumor growth and invasion (Pai et al. 2008). 
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FGFR4, contrary to the other FGFR family members, does not have alternatively spliced 
variants, but its functions appear to be altered by polymorphisms (Ho et al. 2009). There 
are many reports in the literature that implicate FGFR4 in tumorigenesis. The Gly388Arg 
polymorphism is associated with increased risks of several cancers and FGFR4 is 
frequently overexpressed in patients with HCC. The anti-apoptotic effects of FGFR4 have 
been associated with resistance to chemotherapy and knockdown of FGFR4 expression by 
siRNAs in the liver cancer cell line Huh7 was able to suppress α-fetoprotein production 
(Ho et al. 2009, Roidl et al. 2009). However apparently contradictory contradicting effects 
have also been reported, including the observation that the genetic deletion of FGFR4 in 
mice accelerates the progression of DEN-induced HCC (Huang et al. 2009), and the 
overexpression of FGFR4 and KLB induce apoptosis and inhibit tumor cell proliferation in 
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HCC is the most frequent form of primary liver cancer and deadly disease, with limited 
therapeutic options. The only therapeutic agent that has shown some efficacy is the multi-
target kinase inhibitor sorafenib, suggesting the interference with dysregulated cell 
signaling pathway could be exploited for HCC treatment. To this end the identification of 
key signaling pathway in hepatocarcinogenesis, and understanding their extensive 
crosstalk, are essential to devise efficacious therapies and to avert resistance. 
The EGFR signaling system is considered as a “signaling hub” where different growth 
and survival signal converge. This interaction with other signal pathways may occur at 
different levels. The EGFR system is commonly activated in HCC, and is currently being 
evaluated as a therapeutic target in combination therapies. As previously demonstrated 
the EGFR ligand AR, plays a central role in proliferation, survival and chemoresistance of 
cancer cells, including HCC cells and is frequently up-regulated in HCC tissue and cells 
through mechanisms not completely known. 
Another one important signaling pathway, most dysregulated in a number of human 
tumors, including HCC, is the Wnt/β-catenin system. Several mechanisms account for β-
catenin pathway activation in HCC cells, which includes mutations in β-catenin gene or in 
components of the β-catenin degradation complex, as well as dysregulation in the 
expression of Wnt/Frizzled signaling elements. Crosstalks between Wnt/β-catenin 
signaling and EGFR system have been reported in different cell types, including liver 
parenchymal cells. 
Knowing the existence of a variety of crosstalk between the most important signaling 
pathways during hepatocarcinogenesis, the first purpose of this thesis was to evaluate 
whether the expression of AR could be regulated through the β-catenin signaling pathway 
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In second place, knowing that the FGF19 is a soluble growth factor involved in 
hepatocarcinogenesis and an important β-catenin pathway activator, we asked if the AR 
gene expression can be induced by FGF19 through the β-catenin pathway in human HCC 
cells and if the AR up-regulation is required for FGF19-elicited HCC cell proliferation. 
Finally we tried to demonstrate a positive correlation between the AR and FGF19 gene 
expression in human HCC tissue in order to evaluate a possible clinical and therapeutical 
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1. Cell culture and treatments. 
The HCC cell lines HepG2, Hep3B and PLC/PRF5 from ATCC (Rockville, MD) were 
maintained in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 2mM L-glutamine, 100units/mL Penicillin, 100mg/mL Streptomycin and 10% Fetal 
Bovine Serum (FBS) (Castillo et al. 2006, Pardo-Saganta et al. 2009). The human HCC cell 
line Huh7 (0403) was obtained from the Japanese Collection of Research Bioresources 
(JCRB, Tokyo, Japan) and maintained according to their instructions.  
Cells were treated with the GSK3β; inhibitors LiCl and SB-415286 (Sigma, St. Louis, 
MO); the EGFR inhibitor PD153035 (Calbiochem, San Diego, CA); the AR goat polyclonal 
neutralizing antibody (αAR) (#AF262) or the control goat IgG (R&D Systems, Minneapolis, 
MN). 
Medium, Trypsin, FBS and antibiotics were from Gibco/Invitrogen (Paisley, United 
Kingdom). The materials for the cell culture (plates, scrapper, pipettes and plastic tubes) 
were from Costar/Corning (Corning, NY, EEUU) and Sarstedt (Newton, NC, EEUU). 
2. Plasmid constructs and transfections.  
OneShot® Top10 the competent bacteria cells (Invitrogen) were transformed with the 
indicated plasmids using the chemical transformation protocol suggested by 
manufacturer. The transformation reaction was spread in broth (LB, Sigma) containing a 
specific antibiotic (depending on plasmid resistance) and were incubated at 37ºC 
overnight. 
The plasmids were extracted with the kit Endofree Plasmid Maxi Kit (Qiagen, Hilden, 
Germany) and plasmid DNA concentration was measured with a NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific Inc, Wilmintong, DE, EEUU). 
A 1255bp fragment of human AR gene 5’ region, immediately upstream of the 5’ end of 
the mRNA start site, nucleotides -210 to -1464 from the ATG (Plowman et al 1990), was 
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generated by PCR amplification of HepG2 cells genomic DNA using the primers described 
in the Table 1. 
This AR 5’ DNA fragment was cloned upstream from the luciferase reporter gene in the 
pGL3-Basic vector (Promega, Madison, WI). Site-directed mutagenesis of the Tcf-binding 
elements (TBEs) was performed on this construct using the Quick Change Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the protocol supplied by the 
manufacturer. Mutations were as follows:  
 TBE1: CTTTGTA → CTTTGCC; 
 TBE2: CTTTGAA → CTTTGGC; 
 TBE3: TACAAAC → GCCAAAG. 
The primers used for site-directed mutagenesis are reported in the Table 1. 
The expression vectors for the dominant stable β-catenin T41A mutant and the 
dominant negative Tcf4 variant (ΔNTcf4) were kindly given by Dr. Marie-Annick Buendia 
(Pasteur Institute, Paris, France).  
The cells were plated in 60mm dishes until 70% confluence and transiently transfected 
with lipofectamine reagent (Invitrogen) with the wild type and mutant AR-promoter 
reporter constructs, the empty pGL3-Basic vector as control and the TOPflash Tcf reporter 
plasmid (Millipore, Billerica, MA). Cells were also co-transfected with the Renilla luciferase 
reporter vector (Promega) as an internal control for transfection efficiency. Luciferase 
activity in cell lysates was determined using the Dual-Luciferase Reporter Assay System 
(Promega). 
Huh7 cells were stably transfected with the expression vector for β-catenin T41A 
mutant and the empty expression vector (pcDNA3) and subsequently selected in complete 
medium containing 0.6mg/mL of Geneticin sulfate (G418, Invitrogen). After 2 weeks, 
individual colonies were harvested and each transfected clone was expanded. 
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S 5’ CAGCCCACCCGAGTAGCTGGGACTA 3’ 
60ºC 
AS 5’ GTAGGGCGGCGCGCACCTGCCGCTTTATA 3’ 
TBE1 
S 5' TCTGTTGTAGATGTTAAGTAGCCAAAGAGGTTGTCAGAGTTTGAAAC 3' 
55ºC 
AS 5' GTTTCAAACTCTGACAACCTCTTTGGCTACTTAACATCTACAACAGA 3' 
TBE2 
S 5' AAGAATTCATATCCACCTGGCTTTGGCCATTATCGGCTGTGAGATGG 3' 
55ºC 
AS 5' CCATCTCACAGCCGATAATGGCCAAAGCCAGGTGGATATGAATTCTT 3' 
TBE3 
S 5' CATCACGCCCAGCTAATTTCCTTTGGCTTTTTAGTAAAGATGGGGTT 3' 
55ºC 
AS 5' AACCCCATCTTTACTAAAAAGCCAAAGGAAATTAGCTGGGCGTGATG 3' 
Table 1: primers used for amplification and for site directed mutagenesis. 
3. RNA isolation and quantitative real-time PCR (qPCR). 
Total RNA was extracted after homogenization with the TriReagent (Sigma) based on 
the Chomczynsky and Sacchi’s Method (Chomczynsky and Sacchi, N. 1987). The RNA pellet 
was resuspended in sterile water treated with diethyl pyrocarbonate (H2O DEPC, Sigma). 
RNA concentrations were measured with a Nanodrop ND-1000 Spectrophotometer. 
Two µg of total RNA was reverse transcribed into complementary DNA (cDNA), after 
DNase treatment and denaturation at 95ºC, using the M-MLV reverse transcriptase as 
instructed by the manufacturer (Invitrogen). Total RNA (2µg) was mixed with a solution 
containing 50mM Tris-HCl pH 8.3, 75mM KCl, 3mM MgCl2, 10ng/µl random primers, 
0.5mM desoxinucleotides triphosphates (dNTPs: dATP, dTTP, dGTP and dCTP), 5mM 
dithiothreitol (DTT), 1,2U/µl RNase inhibitors (RNase out, Invitrogen) and 6U/µl reverse 
transcription enzyme M-MLV (Invitrogen) and incubated 60 minutes at 37°C. The cDNA 
samples were purified by Spin Columns Centrisep (Princeton Separation, Adelphia, NJ, 
EEUU) and stored at -20°C. 
The differences in the expression of the different genes were analyzed by Real Time 
PCR (qPCR) that was performed by using an iCycler (BioRad, Hercules, CA) and the iQ 
SYBR Green Supermix (BioRad). The quantification of the expression of the mRNA was 
calculated using as the Histone gene as a control with the following formula: 
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2ΔCt = 2 (CT Histone – CT gene of interest) 
The temperature of hybridization and the reading of the fluorescence were different 
depending on each gene but the general reaction conditions were: 
Initial denaturation:  95ºC, 1min 30sec 
Denaturation of each cycle:  95ºC, 30sec 
Hybridization:   XºC, 15sec 
Extension:   72ºC, 25sec 
Lecture:   XºC, 10sec 
Melting curve:    from 70ºC at 99.5ºC in intervals of 0.5ºC (60x) 
We designed all primers to distinguish between genomic and cDNA amplification and 
all PCR (polymerase chain reaction) products have been sequenced to confirm the 
specificity. The sequences of primers used for qPCR are described in the Table 2. 




























AS  ACTTGCCTCCTGCAAAGCAC 
Table 2: primers sequences and hybridation temperatures. 
 
45 cycles 
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4. Chromatin immunoprecipitation (ChIP). 
20x106 cells for each condition were plated and grown in complete DMEM medium. 
After the indicated treatments cells were treated with 1% formaldehyde (Parneac, 
Barcelona) for 10 minutes at room temperature to induce crosslinking DNA-protein. The 
crosslinking reaction was stopped by adding 0.125M glycine during 5 minutes. Cells were 
washed with ice-cold PBS, scrapped in ice-cold PBS containing 1mM PMSF (Sigma) and 
centrifuged at 5000rpm for 5 minutes. The pellets were re-suspended in lysis buffer 
solution (3mM MgCl2,10mM NaCl, 10mM Tris-HCl pH 7.4, 0.5% NP40 (Roche), 1mM PMSF, 
10µg/mL aprotinin (Roche), 10µg/mL leupeptin (Sigma) and incubated in ice 10 minutes, 
disrupted in a potter B (10 strokes) and centrifuged at 5000rpm for 5 minutes. Nuclei 
pellets were re-suspended in lysis buffer solution (50mM Tris-HCl pH 8.1, 10mM EDTA, 
1% sodium dodecyl sulfate (SDS) and protease inhibitors) and incubated 10 minutes in 
ice. 
Samples were sonicated in order to obtain DNA fragments of 500-600pb, centrifuged at 
14000rpm for 10 minutes and supernatants were collected. 
The obtained chromatin was pre-cleared using Dynabeads protein G (Invitrogen) 
previously blocked for 2 hours in orbital agitation with salmon sperm DNA. The samples 
were separated in three tubes: one was incubated with 5µg of the specific antibody (Table 
3), other one with IgG (of the same isotype) and the third without antibody (the last two 
were used as negative controls), overnight at 4ºC in orbital agitation. Subsequently the 
magnetic support was added to each tube for 2 hours at 4ºC in constant agitation. The 
supernatants were collected as total chromatin input. The Dynabeads were then 
resuspended and washed three times with a buffer composed of 2mM EDTA, 50mM Tris-
HCl pH 8.0 and 0.2% sarkosyl, and another four times with the IP washing buffer (100mM 
Tris-HCl pH 9.0, 500mM LiCl, 1% NP40 and 1% deoxycholic acid). Samples were eluted 
with an elution buffer solution (50mM NaHCO3 and 1% SDS) and vortexed during 15 
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minutes. 0.3M NaCl and RNase (100mg/mL, Qiagen) were added to the supernatants of 
and samples were heated at 67ºC overnight to reverse the formaldehyde cross-link. 
The DNA was then precipitated with ethanol for two hours at -80ºC and centrifuged at 
14000 rpm for 15-20 minutes at 4ºC. The pellet were resuspended in Tris-EDTA (TE) 
buffer pH 7.5 containing 10mM Tris-HCl pH 7.5, 5mM EDTA, 0.25% SDS supplemented 
with 15µg of Proteinase K (Sigma) and incubated for 2 hours at 45ºC. 
Afterwards samples RNA were extracted with phenol/chloroform/isoamylic alcohol 
(25:24:1, Invitrogen) and chloroform/isoamilyc alcohol (24:1, Invitrogen) and 
precipitated overnight at -20ºC with NaCl, 5µg of tRNA (Roche), 5µg of glycogen (Roche) 
and a double volume of absolute ethanol. Afterwards samples were centrifuged at 
14000rpm for 20 minutes at 4ºC and the pellets were re-suspended in sterile H2O. 
The AR 5’ regions -1459 to -1287, -987 to -811 and -600 to -364, which include three 
putative Tcf/Lef binding sites previously identified by DNA sequence analysis (Katohy and 
Kathoy 2006), were analyzed by qPCR with the primers described in the Table 4. 
Immunoprecipitations with IgG control antibody gave no amplification products upon 
PCR. Values were normalized to average values of inputs. 
 
 
Table 3: antibodies used for ChIP. 








AS   5’-CACCATCTCACAGCCGATAA-3’ 
TBE3 
S 5’- TGTTGGAAACATCAGGCAAA-3’ 
62ºC/80ºC 
AS   5’- CGTAAGGATTCGCTGAGAGG-3’ 
Table 4: primers sequences. 
antibody manufacture Ref.No 
anti-β-catenin Cell signaling #v9581 
anti-Tcf4 Millipore #05-511 
control rabbit IgG Santa Cruz  Sc-2027 
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5. Western blot analysis. 
The cells were scraped and collected by centrifuging at 4000rpm for 5 minutes in PBS 
in a refrigerated centrifuge. Samples were resuspended in 50-60µl of RIPA lysis buffer 
(150mM NaCl, 50mM Tris pH 7.5, 0.1% SDS, 1% triton X-100, 0.5% sodium deoxycholate, 
1mM sodium orthovanadate, 10mM sodium fluoride, 100mM β-glycerolphosphate and a 
cocktail of protease inhibitors de Roche Diagnostics), sonicated 30 seconds at medium 
intensity, with a Bioruptor sonicator (Diagenode, Liège, Bélgium) and centrifugated at 
13000rpm for 15 minutes in a refrigerated centrifuge. The supernatants were collected 
and quantitated by the Bicinchoninic Acid (BCA, Sigma) Protein Assay. 
SDS-PAGE using 10% resolving gels was used to separate total proteins. A total of 15-
30µg of total protein extract was boiled for 5 minutes in loading buffer 5X (50mM Tris pH 
6.8, 100mM β-mercaptoethanol, 2% SDS, 10% glycerol, 0.01% bromophenol blue) and 
eletrophoresed in running buffer (25mM Tris, 192mM Glycine, 0.1% SDS) on a Protean II 
Minigel Apparatus (Bio-Rad, Sydney, Australia). SDS-PAGE gels were run at 100V until the 
loading dye had reached the end of the stacking gel and then at 100-120V through in the 
resolving gel. Pre-stained molecular weight protein markers (Precision Plus Protein 
Standard Dual Color, Bio-Rad) were used to determine the molecular sizes of the resulting 
bands. 
The proteins separated by SDS-PAGE were electrotransferred onto a nitrocellulose 
membranes (Hybond-C Extra, Amersham Biosciences, Buckinghamshire, UK) using a 
transfer buffer (25mM Tris, 192mM Glycine  and 20% Methanol) for 45 minutes at 4ºC 
using un costant voltage (120V).  
The nitrocellulose membranes were bloqued for 1 hour at room temperature in dry 
milk 5% for not phophorylated protein or bovin serum albumin (BSA) 5% for 
phosphorylated protein in TBS-Tween (TBS-T) (25mM Tris pH 7.5, 200mM NaCl, 0.1% 
Tween 100). Afterwords membranes were incubated overnight with the primary antibody 
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at the concentration recomended by the manufacter in 5% milk or BSA in TBS-T (Table 5). 
Following primary antibody incubation and washing in 0.1% TBS-T (3x5min), membranes 
were incubated 1 hour with the secondary antibody (rabbit or mouse) diluited 1:6000 in 
5% milk or BSA. Afterwords membranes were washed three times in TBS-T (5min) and 
once in TBS 1X (10min). Membranes were developed using the chemiluminescence 
Western Lightning kit (PerkinElmer. Inc, Waltham, MA, EEUU) according to the 
instructions of the supplier using Amersham Hyperfilms ECL (Amersham Biosciences). 




cell signalling #9336 1:1000 5% BSA  Rabbit 
anti-Active β-catenin  
Millipore #05-665  1:1000 5% Milk  Mouse 
anti-Tcf4  
Millipore #05-511 1:1000 5% Milk  Mouse 
Polyclonal anti-β-actin 
antibody  
Sigma #A2066 1:2000 5% Milk  Rabbit 
Table 5: antibodies used for the western blot. 
6. RNA interference.  
Cells were plated in a 6 multiwell plates, in 10% FBS DMEM without antibiotics. 
Subsequently cells were transfected with specific siRNA oligonucleotides (siAR1 and 
siAR2) and control siRNAs (siGL) at a concentration of 100nm/well. The sequences of the 
siRNAs are reported on the Table 6. 
Transfections were performed using the RNasi Mix (Invitrogen) according to the 
manufacturer’s instructions in 10% FBS OPTIMEM without antibiotics, medium was 
change after 6 hours for complete DMEM. Tuelve hours post-transfection medium was 
changed to 0% FBS DMEM and 8 hours after treatments the RNA and proteins were 
extracted from the cells. 
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Gene  Name Primers Manufacter 
siGL 
 S 5' CGUACGCGGAAUACUUCGA [dT] [dT] 
Sigma 
 AS 5' UCGAAGUAUUCCGCGUACG [dT] [dT] 
siAR 
1 
S 5' CCACAAAUACCUGGCUAUA [dT] [dT] 
Dharmacon 
AS 5' UAUAGCCAGGUAUUUGUGG [dT] [dT] 
2 
S 5' AAAUCCAUGUAAUGCAGAA [dT] [dT] 
AS 5' UUCUGCAUUACAUGGAUUU [dT] [dT] 
Table 6: siRNA sequences. 
7. AR determination by ELISA.  
The concentration of soluble AR was evaluated in the cells conditioned media by an 
Enzyme Linked Immunosorbent Assay (ELISA). The cell culture was maintained in 
absence of serum, the conditioned medium was collected and 1mM phenylmethylsulfonyl 
fluoride (PMSF) was added, medium was pre-cleared by centrifugation at 4500rpm for 5 
minutes and then lyophilized.  
This technique is based on the antibody sandwich principle. First, 100µl (2µg/mL 
concentration) of a capture antibody specific to the analyte of interest (monoclonal anti-
AR capture antibody #MAB262, R&D System) is bound to a PVC microtiter plate to create 
the solid phase overnight a room temperature. Unbound antibody is removed by washing 
the plate with a washing buffer (0.05% Tween 20 in PBS pH 7.4). Therefore the remaining 
protein-binding sites were blocked in the coated well by adding a blocking reagent (PBS, 
1% BSA, 5% sucrose and 0.05% NaN3) for 2 hours at room temperature, following by 
wash with the washing buffer.  
A standard curve using recombinant human AR (#AR A7080, Sigma) was prepared in 
double starting to a concentration of 2ng/µl. Samples and controls were prepared in a 
diluent buffer (20mM Tris pH 7.3, 150mM NaCl, 0.1% BSA and 0.05% Tween20) and 
incubated 2 hours at room temperature with the solid phase antibody, which captures the 
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analyte. After 3 washes to remove unbound analyte, a conjugated detection antibody 
(biotinylated anti-human AR antibody, polyclonal, BAF262, R&D System) was added and 
incubated for 2 hours at room temperature. This detection antibody binds to a different 
epitope of the molecule being measured and completes the sandwich. Following 3 washes 
to remove unbound detection antibody, a detection reagent (Streptavidin-HRP) is added in 
concentration of 1:1000 and incubated 1 hour at room temperature. The plate is washed 3 
times, and 100µl of a substrate solution 3,3’,5,5’-tetramethylbenzidine (TMB)/hydrogen 
peroxide is added and color develops in proportion to the amount of bound analyte. The 
color development is stopped with 50µl of stopping solution 2N SO4H2 and the intensity of 
the color is measured at 370nm in the microplate reader 680XR (Bio-Rad).The standard 
curve using recombinant human AR (#AR A7080, Sigma) was used to calculate AR 
concentrations in the conditioned medium. 
8. Immunofluorescence staining. 
Cells were cultured on coverslips. After treatments cells were fixed with 4% 
paraformaldehyde (15min) and subsequently permeabilized with 0.1% Triton X-100. 
After blocking in Supper blocking Buffer (Biorad, Hercules, CA) (30min) fixed cells were 
incubated with anti-β-catenin antibodies (Santa Cruz Biotechnology, #sc-7963) (1:100 in 
1% Albumin) overnight at 4ºC. Slides were washed with saline and incubated with Alexa 
Fluor 488-conjugated rabbit anti-mouse secondary antibody (1:500 in 1% Abumin) 
(Invitrogen, Carlsbad, CA) for 1 ½ h at room temperature, then washed and mounted. 
Finally, sections were counterstained with 4’, 6’-diamidino-2-phenylindole (DAPI) and 
examined under a fluorescence microscope. 
 
MATERIALS & METHODS 
 
Salis Fabiana, Regulation of amphiregulin gene expression by β-catenin signaling in human 
hepatocarcinoma cells: a novel crosstalk between FGF19 and the EGFR system. Tesi di Dottorato in 
Epidemiologia Molecolare dei Tumori. Universitá degli Studi di Sassari 
75 
9. Data mining in gene expression datasets from human HCC 
tissues. 
Data mining was performed using public high-throughput gene expression datasets 
from human HCC tissues obtained from Gene Expression Omnibus (GEO) database. AR and 
FGF19 expression values were obtained from the following sets of data: GSE1898 (90 HCC 
tissue samples) (Lee et al. 2006) and GSE5975 (238 HCC tissue samples) (Jia et al. 2007). 
10. Statistical analysis. 
Statistical analysis was performed with the Graph Pad Prism version 5.00 software 
(Graph Pad Software, San Diego, CA). Experiments were performed at least twice in 
triplicates. Data are means  SEM. Data were compared among groups using the Student t 
test. The Spearman’s correlation coefficient was used to analyse the correlation between 
AR and FGF19 gene expression values obtained from the above-mentioned datasets A P 
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1. Activation of β-catenin signaling induces AR gene expression 
in human HCC cells.  
In order to examine the regulation of AR gene expression through the activation of the 
β-catenin signaling pathway we first used two well-known inhibitors of GSK3β, LiCl and 
SB-415286 (Stambolic et al. 1996; Coghlan et al. 2000). GSK3β is a multifunctional 
serine/threonine kinase implicated in diverse cellular processes including proliferation, 
differentiation, motility and survival. Aberrant regulation of GSK3β has been implicated in 
a range of human pathologies including non-insulin-dependent diabetes mellitus, 
cardiovascular disease, some neurodegenerative diseases, and bipolar disorder and also 
participates in neoplastic transformation and tumor development. One of the most well-
known substrates of GSK3β is β-catenin, and GSK3β is an important regulator of the 
Wnt/β-catenin signaling pathway. GSK3β phosphorylates β-catenin leading to its 
ubiquitination and degradation by the proteasomal pathway. GSK3β inhibition, by 
phosphorylation, prevents it from phosphorylating β-catenin, thus stabilizing β-catenin in 
the cytoplasm. As β-catenin accumulates, it translocates into the nucleus where it binds to 
TCF/LEF complexes and dramatically increases their transcriptional activity (Luo 2009; 
Dahmani et al. 2011; Aberle et al. 1997). 
To demonstrate that, we treated Huh7 cells for 3 and 12 hours with LiCl or SB-415286 
at a concentration of 20mM and 10µM respectively and we performed a western blot 
analysis in order to evaluate the levels of dephosphorylated and active β-catenin which, as 
shown in Figure 17, increase upon stimulation with both LiCl and SB-415286 as compared 
to control cells.  
These data are further confirmed by immunocytochemical staining, which shows, as 
reported in Figure 18, the accumulation and nuclear translocation of β-catenin in the Huh7 
cells treated for 12 hours with LiCl or SB-415286 compared with negative control cells. 
Nuclei were stained with DAPI.  
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Figure 17: Huh7 cells were treated with LiCl (20mM) or the GSK3β inhibitor SB-415286 (10µM) (SB) for the 
indicated time points and active β-catenin was detected by immunoblotting with β-catenin specific antibody 
(dephosphorylated on Ser37 and Thr41). 
 
Figure 18: Immunofluorescent demonstration of increased β-catenin protein levels and nuclear distribution in 
Huh7 cells treated with LiCl (20mM) or SB-415286 (10µM) (SB) for 12h. Representative images are shown. 
We also demonstrate that AR mRNA levels increase in a time and dose dependent 
manner upon LiCl stimulation of Huh7 cells (Figure 19A) as well as in Hep3B cells (Figure 
19B) and HepG2 human HCC cells (Figure 19C). The SB-415286 β-catenin agonist also 
induced AR mRNA expression in all three cell lines (Figure 19A-C). Furthermore we also 
demonstrate that activation of the β-catenin pathway induces AR protein secretion in 
human HCC cells. For this we treated cells with LiCl (20mM) or SB-415286 (10µM) for 24 
hours in serum-free medium, and we detected, in the conditioned medium of Huh7 cells, 
increased levels of AR protein consistently with the up-regulation of AR mRNA previously 
shown (Figure 20). 
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Figure 19: Time- and dose-dependent induction of AR gene expression in Huh7 cells upon β-catenin pathway 
activation by LiCl treatment. The effect of SB-415286 (10µM) (SB) at 24h of treatment is also shown (A) Huh7 
cells, (B) Hep3B cells, (C) HepG2 cells. * P<0.05 vs control, ** P<0.01 vs control. AU: arbitrary units. 
 
 
Figure 20: Huh7 cells were treated with LiCl (20mM) or SB-415286 (10µM) (SB) for 24h in serum-free 
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2. Activation of β-catenin pathway promotes β-catenin and Tcf4 
recruitment to AR promoter in human HCC cells. 
As previously mentioned activation of β-catenin signalling involves its nuclear 
translocation and interaction with members of the TCF/LEF family of transcription 
factors, leading to the formation of regulatory complexes that bind Tcf-binding elements 
(TBEs) on the promoters of target genes (Dahmani et al. 2011; MacDonald et al. 2009, 
White et al. 2012). A previous in silico study on the potential regulation of the expression 
of EGF family members by the Wnt/β-catenin pathway had identified three putative 
consensus TBE sites in the 5’ region of the human AR gene (Katoh and Katoh 2006). These 
sequences are shown in Figure 21.  
To characterize the mechanisms involved in AR gene regulation by β-catenin pathway 
we examined the in vivo binding of Tcf4 and β-catenin to these TBEs indicated as TBE1, 
TBE2 and TBE3. As shown in Figure 22A, ChIP analysis indicated that binding of β-catenin 
to these three TBEs was detected under basal conditions and it was significantly increased 
upon 24 hours of LiCl 20mM treatment of Huh7 cells as compared to control cells. 
Chromatin immunoprecipitation with a Tcf4 specific antibody also showed enhanced 
binding to these TBEs after LiCl stimulation when compared to the controls cells (Figure 
22B). Immunoprecipited genomic DNA was PCR amplified and resolved in agarose gels. 
The induction of Tcf4 and β-catenin binding upon LiCl stimulation to TBEs in AR 5’ region 
was further confirmed by quantitative analysis of immunoprecipitated chromatin (qChIP), 
as indicated in the Methods, shown in Figure 22A and B. These findings indicated that 
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Figure 21: Identification in the human AR promoter sequence of three putative Tcf binding sites (TBE): TBE1, 
TBE2 and TBE3. The positions of these elements, and that of the TATA box, are indicated with numbering in 
reverse starting from the ATG. 
 
 
Figure 22: ChIP assay measuring the binding of β-catenin (A) or Tcf4 (B) to the three AR promoter regions 
encompassing the TBE1, TBE2 and TBE3 sites in control (C) and LiCl (20mM, 24h) treated Huh7 cells. Upper 
panel DNA obtained after immunoprecipitation of chromatin with β-catenin (A) and Tcf4 (B) antibodies from 
control and LiCl treated cells was quantified by qPCR as indicated in Materials and Metods section. Lower 
panel: ChIP assay evaluating the binding of β-catenin (A) and Tcf4 (B) to the three AR promoter regions 
encompassing the TBE1, TBE2 and TBE3 sites in control (C) and LiCl (20mM, 24h) treated Huh7 cells as 
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3. Expression of an active β-catenin mutant promotes AR gene 
expression in human HCC cells. 
To further investigate the involvement of β-catenin in the regulation of AR gene 
expression we stably transfected Huh7 cells with an active β-catenin mutant called β-
catenin T41A or the corresponding empty vector, pcDNA 3.1. This β-catenin T41A mutant 
protein has increased stability, and has been previously shown to significantly up-regulate 
the expression of β-catenin target genes (Renard et al 2007; Wei et al. 2000). Consistently 
we observed increased β-catenin protein levels in β-catenin T41A expressing Huh7 cells 
compared with control cells stably transfected with the empty expression vector, as well 
as increased mRNA expression of the Wnt/β-catenin target gene Tbx3 (Renard et al 2007) 
(Figure 23A and B). T41A β-catenin expressing Huh7 cells also displayed increased levels 
of AR mRNA and secreted more AR protein to the culture medium (Figure 24A and B). 
These observations confirmed the notion that β-catenin pathway activation can trigger AR 
gene expression in HCC cells. To gain further insight on the mechanisms involved in the 
regulation of AR gene transcription by β-catenin/Tcf, we performed a site-directed 
mutation of the TBE sites found in AR 5’ regulatory region, in the context of a 1255bp AR 
promoter luciferase reporter plasmid as described in Materials and Methods section. Huh7 
cells stably transfected with the control vector pcDNA3.1 or with the T41 β-catenin active 
mutant were transiently transfected with the empty luciferase reporter plasmid (pGL3) or 
with the wild type AR promoter luciferase reporter construct (ARwt pGL3). Transfection 
of the wild type AR promoter construct in Huh7 cells expressing the active T41A β-catenin 
mutant resulted in a significant stimulation of AR promoter activity compared to control 
Huh7 cells (Figure 25).  
Huh7 cells expressing the T41A β-catenin active mutant were also transfected with 
three AR promoter constructs in which the three TBE sites had been individually mutated 
(ART1mut pGL3, ART2mut pGL3 and ART3mut pGL3). The mutation in either TBE site 
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markedly reduced T41A β-catenin-induced AR promoter activity (Figure 25). Altogether, 
these evidences indicate that β-catenin pathway activation triggers AR gene expression in 
HCC cells and that AR would be a direct transcriptional target of the β-catenin/Tcf 
complex. 
 
Figure 23: (A) Western blot of β-catenin protein levels in Huh7 cells stably transfected with an empty control 
vector (pcDNA3.1), or with the same vector harbouring a human stable β-catenin mutant (T41A β-catenin). (B) 
mRNA expression levels of the β-catenin target gene Tbx3 in Huh7 cells stably transfected with control vector 
(pcDNA3.1) or with the T41A β-catenin active mutant. ** P<0.01 vs control. 
 
Figure 24: (A) Expression levels of AR mRNA in Huh7 cells stably transfected with control vector (pcDNA3.1) 
or with the T41A β-catenin active mutant. * P<0.05 vs control. (B) AR protein contents as determined by ELISA 
in the conditioned media of Huh7 cells stably transfected with the control vector pcDNA3.1 or with the T41A 
β-catenin active mutant. Media was collected after 24h culture in serum-free conditions. ** P<0.01 vs control.  
RESULTS 
 
Salis Fabiana, Regulation of amphiregulin gene expression by β-catenin signaling in human 
hepatocarcinoma cells: a novel crosstalk between FGF19 and the EGFR system. Tesi di Dottorato in 
Epidemiologia Molecolare dei Tumori. Universitá degli Studi di Sassari 
86 
 
Figure 25: Huh7 cells stably transfected with the control vector pcDNA3.1 or with the T41 β-catenin active 
mutant, were transiently transfected with the empty luciferase reporter plasmid (pGL3) or with the wild type 
AR promoter luciferase reporter construct (ARwt pGL3). Huh7 cells expressing the T41A β-catenin active 
mutant were also transfected with three AR promoter constructs in which the three TBE sites had been 
individually mutated (ART1mut pGL3, ART2mut pGL3 and ART3mut pGL3). Luciferase activity was measured 
as described in Methods. * P<0.05 vs ARwt pGL3-derived luciferase activity in pcDNA3.1 transfected cells. § 
P<0.05 vs ARwt pGL3-derived luciferase activity in T41A β-catenin transfected cells. AU: arbitrary units. 
4. β-catenin activation of HCC cell proliferation is mediated in 
part through the induction of AR. 
Signaling through the β-catenin pathway has been thoroughly demonstrated to 
contribute to HCC cell growth (Renard et al 2007; Merle et al. 2004; Zeng et al. 2007). This 
is supported in part by the growth-promoting effects of constitutively active β-catenin 
mutants, such as S33Y, in human fetal hepatoblasts and HCC cells (Wege et al. 2011). We 
observed that Huh7 cells stably expressing the T41A β-catenin active mutant showed 
enhanced proliferation compared with cells transfected with the control empty vector 
pcDNA3.1 (Figure 26). Interestingly, the growth of T41A β-catenin expressing Huh7 cells 
was significantly reduced when cells were treated with the EGFR inhibitor PD153035, or 
incubated whit a specific AR neutralizing antibodies (αAR) for 72 hours as compared with 
cells treated with control purified goat IgG (αIgG) or Huh7 cells transfected with the 
empty vector pcDNA3.1 (Figure 27). In cells treated with PD153035 we found an 87.7% of 
reduction over the stimulation conferred by T41A β-catenin expression, while with the 
specific AR neutralizing antibody we detect a reduction of 46.1%. The combination of αAR 
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and PD153035 did not further increase the already potent effect of the EGFR inhibitor. The 
involvement of AR on the enhanced proliferation of T41A β-catenin expressing cells was 
additionally demonstrated upon AR gene expression knockdown with AR specific siRNAs 
(Figure 28). These findings indicate that at least part of the growth-promoting effects of β-
catenin pathway activation may be mediated through the up-regulation of AR gene 
expression.  
 
Figure 26: Proliferation of Huh7 cells stably transfected with control vector pcDNA3.1 or the T41A β-catenin 
active mutant. * P<0.05 and ** P<0.01 vs pcDNA3.1 transfected cells.  
 
Figure 27: Proliferation induced by T41A β-catenin active mutant is attenuated by AR neutralizing antibodies 
or the EGFR inhibitor PD153035. T41A β-catenin expressing Huh7 cells were incubated in the absence or 
presence of AR neutralizing antibodies (αAR, 20µg/mL), control purified goat IgG (IgG, 20µg/mL) or 
PD153035 (1µM, PD15) for 72h and cell proliferation relative to pcDNA3.1 transfected cells was measured. 
The effect of these treatments on control pcDNA3.1 transfected cells is also shown. * P<0.05 vs pcDNA3.1 
transfected cells, § P<0.05 vs untreated T41A β-catenin transfected cells. 
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Figure 28: Proliferation of Huh7 cells stably transfected with control vector pcDNA3.1 or the T41A β-catenin 
active mutant silenciated with siGL or siAR* P<0.05 and ** P<0.01 vs pcDNA3.1 transfected cells. 
5. FGF19 activates β-catenin signalling and AR gene expression 
in human HCC cells. 
Aberrant activation of the Wnt/β-catenin pathway in HCC can be accounted for by 
mutations in the CTNNB1 gene as well as by altered expression of ligands, receptors and 
inhibitors of the Wnt pathway (Dahmanin et al. 2011, Bengochea et al. 2008). In addition, 
β-catenin signalling can be activated through crosstalks with other signalling pathways 
deregulated in HCC (Dahmanin et al. 2011, Pai et al. 2008; Desbois-Mouthon et al. 2001; 
Hoshida et al. 2009; Yang et al. 2011). Among these pathways the one driven by FGF19, 
and its tyrosine kinase receptor FGFR4, is perhaps the best characterized in its functional 
interaction with the β-catenin system in HCC cells (Sawey et al. 2011). Activation of β-
catenin by FGF19 has been already shown in Huh7 cells (Sawey et al. 2011). We decide to 
examine if this response could be extended to Hep3B cells. Interestly, compared to other 
HCC cell lines, Hep3B cells expressed higher basal levels of FGF19 (Figure 29A), FGFR4 
(Figure 29B), β-Klotho (Figure 29C) and AR (Figure 29D) mRNA. As shown in Figure 30, 
treatment with FGF19 (50ng/mL), for 24 hours, increased luciferase activity in cells 
transfected with Tcf-luciferase reporter plasmid as compared to controls. Upon FGF19 
treatment cells also displayed increased levels of active dephosphorylated β-catenin and 
phospho-GSK3β as analyzed by immunoblotting showed in Figure 31, and showed 
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elevated mRNA levels of the Wnt/β-catenin target gene Tbx3 (Renard et al. 2007) (Figure 
32)when compared to control cells after 5 hours of stimulation with of FGF19. 
We next evaluated if FGF19 could affect AR gene expression in HCC cells. FGF19 
treatment at different concentration for 5 hours resulted in a dose and time-dependent 
increase in AR mRNA levels (Figure 33A and B) and in an enhanced accumulation of AR 
protein in the cells conditioned media after a treatment for 24 hours with FGF19 (Figure 
33C) in both Hep3B and Huh7 cells. 
 
Figure 29: mRNA basal levels of FGF19 (A), FGFR4 (B), β-Klotho (C) and AR (D) mRNA in different HCC cell 
lines. 
 
Figure 30: Hep3B cells transfected with a Tcf-regulated reporter vector were treated or not with FGF19 
(50ng/mL) for 24h and then was measured luciferase activity. *P<0.05 vs control (C) cells.  
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Figure 31: Hep3B cells were treated or not with FGF19 (50ng/mL, 10min) and active β-catenin or 
phosphorylated GSK3β (p-GSK3β) were detected by western blotting. Representative blots of two experiments 
performed in duplicates are shown. 
 
Figure 32: mRNA levels of the β-catenin target gene Tbx3 in Hep3B cells treated or not with FGF19 (50ng/mL, 
5h). **P<0.01 vs control.  
 
 
Figure 33: (A) Dose-dependent induction of AR expression (mRNA) in Hep3B and Huh7 cells treated with the 
indicated concentrations of FGF19 for 5h. (B) Time-dependent induction of AR expression (mRNA) in Hep3B 
and Huh7 treated with 50ng/mL of FGF19 at the time indicated. (C). AR protein contents were determined by 
ELISA in the conditioned media of FGF19 treated (50ng/mL, 24h) or control (C) in Hep3B and Huh7 cells. 
*P<0.05 vs control ** P<0.005 vs control cells. AU: arbitrary units. 
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6. Inhibition of β-catenin activity by dominant negative Tcf4 
(ΔNTcf4) reduces basal and FGF19-induced AR gene 
expression in HCC cells. 
To evaluate the role played by the β-catenin system in FGF19-mediated AR expression, 
we made use of a previously reported dominant negative ΔNTcf4 expression vector 
(Renard et al. 2007). First we transiently transfected HepG2 cells, which express a more 
stable truncated β-catenin allele (Wege et al. 2011; Yuzugullu et al. 2009), with the control 
pcDNA3.1 vector or with the ΔNTcf4 expression vector. As shown in Figure 34A, we 
demonstrated increased Tcf4 protein levels in ΔNTcf4 transfected HepG2 cells analysed by 
western blotting as compared with control cells. We also demonstrated that expression of 
ΔNTcf4 resulted in reduced basal expression of the Wnt/β-catenin target gene Tbx3 and 
also in decreased AR mRNA levels, confirming the biological activity of this dominant 
negative Tcf4 mutant and the regulation of AR gene expression in response to the 
manipulation of the β-catenin pathway (Figure 34B and C).  
Next we examined the response of ΔNTcf4 expressing HCC cells to FGF19 treatment. 
Huh7 cells were transiently transfected with the control pcDNA3.1 vector or with the 
ΔNTcf4 cDNA. The western blot analysis shown in Figure 35A, displays Tcf4 protein levels 
in control and ΔNTcf4 transfected Huh7 cells 24 hours after transfections. Transfected 
cells were treated or not for 5 hours with FGF19 (50ng/mL) and we observed that the up-
regulation of Tbx3 expression in Huh7 cells treated with FGF19 was attenuated in cells 
expressing ΔNTcf4 compared to cells transfected with control plasmid, and a similar 
response was observed regarding AR expression (Figure 35B and C). 
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Figure·34: HepG2 cells, that express an active mutant β-catenin allele, were transiently transfected with the 
control pcDNA3.1 vector or with this vector harbouring ΔNTcf4 cDNA. (A) Tcf4 protein levels in control and 
ΔNTcf4 transfected HepG2 cells analyzed by western blotting 24h after transfections. In these cells were also 
analyzed the mRNA levels of the β-catenin target gene Tbx3 (B) and those of AR (C). *P<0.05 vs cells 
transfected with pcDNA3.1. 
 
Figure 35: Huh7 cells were transiently transfected with the control pcDNA3.1 vector or with the ΔNTcf4 
cDNA. (A) Tcf4 protein levels in control and ΔNTcf4 transfected Huh7 cells analyzed by western blotting 24h 
after transfections. Transfected cells were then treated or not with FGF19 (50ng/mL, 5h), and the mRNA levels 
of the the β-catenin target gene Tbx3 (B) and those of AR (C) were measured. *P<0.05 vs control cells (C) 
transfected with pcDNA3.1. §P<0.05 vs cells transfected with pcDNA3.1 and treated with FGF19.  
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7. Transactivation of AR promoter by FGF19 treatment depends 
on the integrity of TBE sites. 
To further evaluate the implication of β-catenin signalling on the FGF19-mediated 
regulation of AR gene expression, we examined the response of the above-described wild 
type AR promoter luciferase reporter construct and the three TBE mutants to FGF19 
treatment. Hep3B cells were transiently transfected with the empty luciferase reporter 
plasmid (pGL3), with the wild type AR promoter luciferase reporter construct (ARwt 
pGL3) and with the three AR promoter constructs in which the three TBE sites had been 
individually mutated (ART1mut pGL3, ART2mut pGL3 and ART3mut pGL3). Cells were 
treated with FGF19 for 12 hours and luciferase activity was measured as described in 
Materials and Methods. As shown in Figure 36, FGF19 stimulation resulted in a significant 
increase in AR promoter activity. In line with our previous findings in T41A β-catenin 
active mutant expressing cells, the FGF19-triggered activation of AR promoter was 
markedly reduced when either TBE site was mutated.  
 
Figure 36: Cells were treated as indicated with FGF19 (25ng/mL, 12h) and luciferase activity was measured as 
described in Methods. *P<0.05 vs untreated ARwt pGL3 transfected cells. §P<0.05 vsARwt pGL3 transfected 
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8. Functional relevance of AR up-regulation in FGF19-induced 
HCC cell proliferation. 
FGF19 has been recently identified as a new growth factor capable of inducing the 
proliferation of HCC cells and as a driver gene in hepatocarcinogenesis (Sawey et al. 2011; 
Desnoyers et al. 2008; Miura et al. 2012). Induction of Cyclin D1 expression by FGF19 
involves the activation of the β-catenin pathway, and was found to be essential for the 
promotion of HCC cell growth (Sawey et al. 2011). Considering that AR is a mitogenic 
factor for HCC cells (Castillo et al. 2006; Desbois-Mouthon et al. 2006), and an FGF19 
target gene according to our current findings, we examined the role of FGF19-induced AR 
in HCC cell proliferation. To do so we knocked down AR expression by transfecting Hep3B 
cells with AR-specific (siAR) or control siRNAs (siGL) and 24 hours later cells were treated 
with FGF19 for 5 hours. As shown in Figure 37A, AR mRNA levels elicited by FGF19 
treatment were effectively reduced upon transfection with AR-specific siRNAs when 
compared with those induced in cell transfected with control siGL. Interestingly the 
stimulation of Cyclin D1 gene expression induced by FGF19, that is two-fold over controls, 
was blunted when AR mRNA levels were knocked down (Figure 37B) and we also shown 
in Figure 37C the effect of AR-specific siRNA transfection on AR protein concentration in 
Hep3B cells conditionated medium. This suggested that AR would be an important 
mediator of FGF19 effects on the expression of this key cell cycle regulatory gene. To 
further explore the role of AR in the proliferative effects of FGF19 we measured the 
growth of Hep3B cells treated with FGF19 in the presence or absence of specific AR 
neutralizing antibodies (αAR,), control purified goat IgG (αIgG) or PD153035 (PD15) for 
48 hours. Under these conditions we could demonstrate a significant reduction, of an 
88.7%, in FGF19-induced cell proliferation that was not observed in cells incubated with 
control IgGs (Figure 38). A role for AR/EGFR signalling in FGF19-mediated cell 
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proliferation was further supported by the inhibitory effects of the EGFR inhibitor 
PD153035 on FGF19-mediated cell growth (Figure 38). 
 
Figure 37: Hep3B cells were transfected with control siRNAs (siGL) or AR specific siRNAs (siAR) and 24h later 
cells were treated with FGF19 (25ng/mL, 5h). mRNA levels of the the AR (A) and Cyclin D1 (B) were measured. 
*P<0.05 vs siGL transfected control (C) cells. §P<0.05 vs siGL transfected and FGF19 treated cells. (C) AR 
protein concentration in condiotioned medium from siGL and siAR transfected Hep3B cells was determined by 
ELISA 72 hours after transfections. * P<0.05 vs siGL transfected control. AU: arbitrary units.  
 
 
Figure 38: Proliferation induced by FGf19 is attenuated by AR neutralizing antibodies or the EGFR inhibitor 
PD153035. Hep3B cells were incubated with FGF19 (25ng/mL) as indicated in the absence or presence of AR 
neutralizing antibodies (αAR, 20µg/mL), control purified goat IgG (IgG, 20µg/mL) or PD153035 (1µM, PD15) 
for 48h, and cell proliferation relative to untreated cells was measured. The effect of αAR and PD153035 on 




Salis Fabiana, Regulation of amphiregulin gene expression by β-catenin signaling in human 
hepatocarcinoma cells: a novel crosstalk between FGF19 and the EGFR system. Tesi di Dottorato in 
Epidemiologia Molecolare dei Tumori. Universitá degli Studi di Sassari 
96 
9. Correlation between FGF19 and AR gene expression in human 
HCC tissues. 
To further support our present experimental observations on the regulation of AR gene 
expression by FGF19 in human HCC cell lines we analyzed previously published 
microarray data from two independent gene expression profiling studies. Data was 
available from Gene Expression Omnibus (GEO) database for 90 and 239 HCC tumor 
tissues respectively (Lee et al. 2006; Jia et al. 2007). As shown in Figure 39A and B, our 
data-mining approach revealed a significant positive correlation between FGF19 and AR 
mRNA levels in these ample groups of human HCC tissues. In addition, we also examined 
the expression of AR and FGF19 in the two subclasses of tumors with differential 
prognosis that were identified in the GSE1989 data set according to their gene expression 
profile (Lee et al. 2006). Interestingly, we found that the expression of AR and FGF19 gene 
was higher in the subclass of tumors with strong cell proliferation and anti-apoptosis gene 
expression signatures, corresponding to patients with poorer prognosis (reduced 
survival) (Lee et al. 2006) (Figure 39C and D).  
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Figure 39: Gene expression data was obtained for AR and FGF19 from two independent microarray studies and 
correlation of expression levels was analyzed as described in Methods. (A) AR and FGF19 gene expression 
values were obtained from the GSE1898 dataset (90 HCC tissue samples) and showed a significant positive 
correlation r = 0.18, P<0.05. (B) AR and FGF19 gene expression values were obtained from the GSE5975 dataset 
(238 HCC tissue samples) and showed a positive correlation r = 0.25, P<0.0001. Gene expression data of AR (C) 
and FGF19 (D) in the subclasses of tumors corresponding to patients with poor and better survival originally 
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The EGFR ligand AR is increasingly recognized as a potent oncogenic factor over-
expressed in a variety of human cancers including HCC (Busser et al. 2011; Berasain et al. 
2007a). AR has been demonstrated to participate in most of the characteristic traits of 
transformed cells including self-sufficiency in generating growth signals, limitless 
replicative potential, tissue invasion and metastasis, angiogenesis and resistance to 
apoptosis. The mechanisms responsible for AR upregulation in transformed cells are 
complex and not fully understood and may vary from one tumor subtype to another. In 
addition, it is difficult to assess whether AR mediates the acquisition of these various 
neoplastic phenotypes by itself or in cooperation with other growth factors and/or 
receptors. However, the intrinsic role of AR in tumorigenesis has been demonstrated in 
multiple types of cancer by direct and/or indirect mechanisms without compensation by 
other EGF family members. On the other hand, even if the EGFR is the only receptor for AR, 
some studies have shown that AR is able to activate other receptors. Various molecules are 
known to crosstalk with the EGFR, such as cMET (Puri and Salgia 2008), integrins (Ricono 
et al. 2009), G-protein coupled receptors (Thomas et al. 2006) and the androgen receptor 
(Recchia et al. 2009). Moreover, direct interactions or heterodimerization between the 
ErbB members have been well characterized (Yarden and Sliwkoski 2001), as have 
interactions with other membrane receptors, such as the PDGFR (Saito et al. 2001) and the 
IGF1R (Morgillo et al. 2006). Thus, the AR-induced oncogenic signaling network is 
dramatically more complex than previously thought. AR has pleiotropic effects on cancer 
cells, and it may function as a stimulatory or inhibitory growth factor depending on the 
phenotype of and environment surrounding a given cell (Busser et al. 2011).  
The lack of clinical efficacy of existing systemic chemotherapies and subsequent dismal 
prognosis in unresectable HCC patients with macrovascular invasion or extrahepatic 
metastasis have prompted many biologic and clinical researchers to study in detail the 
molecular mechanisms implicated in hepatocarcinogenesis. As known the molecular 
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pathogenesis of HCC is complex and heterogeneous, comprising a multistep process that 
accounts for the serial accumulation of genomic alterations involved in the development 
and progression of the tumor (Farazi and de Pinho 2006; Fransvea et al. 2009). Further 
understanding of pathogenetic characterization of HCC at the molecular level, which 
mainly consists of the specific interaction of both the extracellular growth factors-
receptors and the intracellular signal transduction pathways, also helps researchers to 
identify the potential therapeutic targets in a certain step of signaling cascades for the 
treatment of this tumor (Song 2009). A multitude of different molecular signaling 
pathways are affected in liver cancer cells making it difficult to focus molecular 
treatments. Of major interest are the growth factors and their receptors as well as their 
signaling pathways. The molecular targeting of these factors has become a promising 
approach for the effective treatment of HCC. HCC is highly resistant to conventional 
chemotherapy. However, the impressive advances in the knowledge of tumor biology 
taken place during the last years and the remarkable success of targeted therapy in other 
tumors (either alone or in combination with cytostatics) has opened promising avenues 
for HCC therapy. In HCC multiple molecular alterations ensure the incessant growth of the 
neoplastic cells. Anti-EGFR agents were initially tested for the treatment of epithelial 
cancers such as non-small-cell lung cancer (NSCLC), in which the expression and function 
of the EGFR signaling system is dysregulated (Dannemberg et al. 2005; Ciardiello and 
Tortora 2008). Two classes of EGFR antagonists are currently available: anti-EGFR 
monoclonal antibodies and small-molecule EGFR tyrosine kinase inhibitors (Ciardiello and 
Tortora 2008). Monoclonal antibodies, such as cetuximab, bind to the extracellular domain 
of the EGFR, blocking ligand binding and receptor activation (Ciardiello and Tortora 2008; 
Sattler et al. 2008). Tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, 
compete with ATP to bind to the intracellular catalytic domain of EGFR tyrosine kinase 
and inhibit downstream signaling from the receptor (Ciardiello and Tortora 2008; Sattler 
et al. 2008). Phase 2 trials with the EGFR TKI erlotinib have yielded encouraging results in 
DISCUSSION 
 
Salis Fabiana, Regulation of amphiregulin gene expression by β-catenin signaling in human 
hepatocarcinoma cells: a novel crosstalk between FGF19 and the EGFR system. Tesi di Dottorato in 
Epidemiologia Molecolare dei Tumori. Universitá degli Studi di Sassari 
103 
advanced HCC (Philip et al. 2005). However, the somatic mutations in exons 18 to 21 of 
EGFR that correspond to the response of non–small cell lung cancers to gefitinib (Lynch et 
al. 2004) have not been demonstrated in HCC, suggesting that this therapy may not be 
useful as a single-agent therapy for HCC (Su et al. 2005). Combination therapies may prove 
more effective because blockade of EGFR by monoclonal antibodies or TKIs can enhance 
the antitumor activity of radiation and conventional chemotherapeutic agents (Huether et 
al. 2005a; Huether et al. 2005b; Zhu et al. 2005; Buckley et al 2008). Crosstalks with other 
signaling systems that are also dysregulated in HCC, such as the IGF2/IGF1R, and the 
constitutive activation of downstream signaling effectors, have been invoked. It was 
demonstrated that while IGF-2 exerted its mitogenic effect on HCC cells through AR 
mediated transactivation of the EGFR, its pro-survival activity was mediated through the 
PI3K pathway and was completely resistant to EGFR inhibitors (Desbois-Mouthon et al. 
2006). Interestingly, combination of EGFR and IGF1R inhibitors overcomes resistance to 
EGFR blockade and results in enhanced HCC cell killing in preclinical studies (Höpfner et 
al. 2008; Desbois-Mouthon et al. 2006). Moreover, simultaneous targeting of downstream 
signaling effectors of the EGFR and IGF1R pathways such as mTOR enhanced therapeutic 
efficacy in experimental models (Höpfner et al. 2008; Villanueva et al. 2008). These 
findings highlight the molecular complexity of HCC and provide a rationale to test 
combination of targeted therapies in HCC patients. These combinations may also include 
inhibitors of the COX2 system, which as previously stated extensively crosstalks with the 
EGFR axis (Wu et al. 2006) or newly developed inhibitors of ADAM17, which have shown 
promising results in the inhibition of colorectal cancer cell growth (Merchant et al. 2008). 
Additionally, although ErbB2 overexpression is not common in HCC, given the capacity of 
ErbB receptors to form heterodimers and the potent intracellular signaling generated 
from heterodimeric complexes (Bublil et al. 2007), a dual EGFR and ErbB2 inhibitor, 
lapatinib, is currently being tested in experimental HCC and early clinical trials (Llovet and 
Bruix 2008; Berasain et al. 2009). 
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Most probably, the combination of agents with different molecular targets as the 
growth factor receptor inhibitors or cytostatics will improve the clinical response in 
patients with advanced HCC with tolerable and manageable side effects. Furthermore, the 
use of targeted therapies such as Sorafenib, that are already approved for therapy in 
advanced HCC, might also improve HCC recurrence in patients who undergo resection, 
local ablation and transarterial chemoembolization, which is currently being tested in 
several ongoing clinical trials (Faloppi et al. 2011). Since the blockade of a specific target 
can be overcome by other molecular abnormalities, it is likely that HCC could easily 
develop resistance to compounds that hit a single molecule. Drugs designed to block 
different growth-promoting pathways (promiscuous drugs such as multiple kinase 
inhibitors) or combination of different targeted therapies might however attain success in 
the control of liver cancer. As shown in the case of breast cancer, targeted therapy against 
molecules conveying growth-promoting signals may render HCC sensitive to specific 
chemotherapeutic protocols. In the future methods to analyse the molecular signature of 
each HCC might make possible to select the appropriate combination of targeted therapies 
that should be used in the particular patient. However toxic side effects of drug 
combinations will be a risk especially in patients with underlying liver cirrhosis and/or 
poor liver function (Avila et al. 2006). AR is also involved in resistance to several cancer 
treatments and therefore constitutes a promising therapeutic target and a validable 
predictive and prognostic biomarker. Down-regulation of AR expression and availability, 
as well as the use of AR-neutralizing antibodies, have been demonstrated to attenuate the 
growth of hepatocellular carcinoma cells (Castillo et al. 2006) and abolish the anti-
apoptotic activity of AR in lung adenocarcinoma cells (Hurbin et al. 2002), showing 
promising pre-clinical results suggesting that these strategies could enhance the 
effectiveness of other targeted and conventional antitumoral approaches (Busser et al. 
2011; Blivet-Van Eggelpoёl et al. 2012; Berasain et al. 2007a; Miyamoto et al. 2009). To 
this end, understanding the mechanisms leading to AR overexpression in cancer cells, 
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including HCC cells is an important albeit unresolved issue (Busser et al. 2011). Through 
different complementary approaches we demonstrate in this study that AR gene 
expression can be activated in human HCC cells by β-catenin signalling, a key signalling 
pathway in hepatocarcinogenesis (Nault and Zucman-Rossi 2011; Avila et al. 2006; 
Breuhahn et al. 2010; Whittaker et al. 2010; Calvisi et al. 2012; Dahmanin et al. 2011; 
Bengochea et al. 2008). 
Various molecular and genetic factors participate to the aberrant activation of the 
Wnt/β-catenin pathway in HCC. Firstly, mutations are frequently identified in genes 
encoding for the main actors of the pathway. Gain-of-function mutations of CTNNB1 
(encoding for β-catenin) are encountered in about one third of HCCs and define CTNNB1 
as the most frequently mutated gene in HCCs. Conversely, loss-of-function mutations of 
negative regulators of the pathway are also observed, namely mutations of the AXIN1 and 
AXIN2 genes (<5%) and of the APC gene (exceptional). Beside such mutational events, the 
Wnt/β-catenin pathway can be also activated in HCCs as a consequence of a deregulated 
dialogue between the tumor cells and their microenvironment. For instance, an autocrine 
Wnt stimulation loop can be established following epigenetic events that change the 
expression profiles of the ligands, the extracellular inhibitors and the receptors of the Wnt 
family. A modified crosstalk with other signaling pathways such as HGF or TGF-β can also 
account for the aberrant activation of the Wnt/β-catenin pathway in HCCs (Dahmanin et 
al. 2011). 
AR gene expression was regulated at transcriptional level by different factors involved 
in cancer. An evolutionarily conserved cAMP response element (CRE) sequence exists 
close to the transcriptional start site of the AR gene. It has been demonstrated (Comerford 
et al. 2003, Taylor et al. 1999, Taylor and Colgabn 1999) a role for the CRE binding protein 
(CREB) in controlling hypoxia-regulated gene expression. CREB was initially described as 
a signal-dependent activator of genes such as somatostatin, via PKA-dependent 
phosphorylation of Ser133 (Andrisani and Dixon 1990; Maxwell and Rotcliffe 2002; Mayr 
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and Montminy 2001). However, it has been reported (Comerford et al. 2003; Taylor et al. 
1999; Taylor et al. 2000; Zhao and Brinton 2004) that CREB may act as a repressor for 
genes including TNF-α. Thus CREB plays an ambiguous role in the regulation of 
transcription that appears to be gene specific. In each case, however, CREB binds to an 8bp 
palindrome (5’-TGACGTCA-3’) known as the CRE that regulates transcription. Hypoxic 
sensitivity of the amphiregulin promoter is retained in a short fragment directly upstream 
from the TATA box that contains a sole CRE motif. Interestingly, this motif was recently 
demonstrated to mediate amphiregulin expression in response to prostaglandin E2 (Shao 
et al. 2003). It is known that hypoxia alters CREB expression and subsequently 
transcriptional activity in intestinal epithelial cells, an event dependent on decreased 
activity of protein phosphatase-1γ (Taylor et al. 1999; Taylor and Colgan 1999). Thus 
hypoxia activates intestinal epithelial amphiregulin expression in transformed cells in a 
manner dependent on functional activity of a CRE motif situated 37bp upstream of the 
transcriptional start site. The hypoxia elicited amphiregulin expression may contribute to 
continued cell proliferation in focal areas of hypoxia found in a range of epithelial tumors 
(O’Reilly et al. 2005). BRCA1 (Breast Cancer 1) has been reported to regulate transcription 
on a variety of promoters, however on its own binds DNA only in a sequence non-specific 
manner (Paull et al. 2001, Simons et al. 2006). BRCA1 can regulate transcription by 
interacting with other transcription factors which can bind to specific sites on DNA and in 
this way BRCA1 alters the function of these transcription factors (Mullan et al. 2006; 
Benezra et al. 2003). Two independent BRCA1-response elements has been identified on 
the AR promoter located at −202/−182 and +19/+122 positions and exist a clear 
connection between the tumor suppressor BRCA1 loss of function and the AR 
upregulation, important for the development and progression of breast cancer (Lamber et 
al 2010). Here we provide evidence showing that AR is a transcriptional target of the β-
catenin/Tcf4 complex, including the demonstration of direct binding of β-catenin and Tcf4 
to three putative TBE sites in the AR promoter region upon β-catenin pathway activation. 
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Endogenous AR expression and secretion to the extracellular medium was induced in HCC 
cells in response to the ectopic expression of the dominant stable β-catenin mutant T41A 
(Renald et al. 2007). Conversely, AR mRNA levels, together with those of the well-
characterized β-catenin target gene Tbx3 (Renald et al. 2007), were reduced by the 
expression of a dominant ΔNTcf4 in HepG2 cells, which express a stable β-catenin allele of 
75KDa (Renald et al. 2007; Zeng et al. 2007; Wege et al. 2011). Furthermore, AR promoter-
reporter activity triggered by the expression of this active β-catenin variant was reduced 
upon mutation of the TBE sites within this AR 5’ region. Together, these observations 
strongly suggest that AR is a target of β-catenin signalling in human HCC cells. 
Nevertheless, β-catenin signalling activates a wide variety of target genes that putatively 
could be involved in HCC tumorigenesis and malignant behaviour (Dahamanin et al. 2011; 
Renald et al. 2007; White et al. 2012; Nejak-Bowen and Monga 2011). In this context, 
establishing the functional significance of β-catenin-stimulated AR gene expression was 
therefore important. Expression of active β-catenin variants such as the S33Y mutant in 
Huh7 cells has been shown to increase their growth (White et al. 2012). Here we 
demonstrate that the T41A β-catenin mutant also enhanced Huh7 cell proliferation. 
Interestingly, proliferation of T41A β-catenin expressing Huh7 cells was significantly 
reduced when EGFR activity was inhibited with PD153035, and in the presence of specific 
AR-neutralizing antibodies. These findings demonstrate that increased AR expression in 
response to β-catenin pathway activation indeed plays a role in the growth elicited by 
enhanced β-catenin signalling in HCC cells. 
Functional crosstalk between Wnt-triggered signalling and the EGFR system have been 
previously identified in other cancer cells of epithelial origin such as breast cancer cells, 
where Wnt overexpression activates signaling via EGFR. In HC11 mammary epithelial 
cells, constitutive expression of Wnt1 and Wnt5a accompanies activation of EGFR and 
MAPK (Hu and Li 2010). In these cells Wnt signalling increased the availability of EGFR 
ligands, leading to EGFR transactivation, cyclin D1 expression and cell proliferation 
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(Civenni et al. 2003; Schlange et al. 2007). However, these effects occurred through 
mechanisms independent from the canonical Wnt signalling pathway, and were linked to 
Src-mediated activation of the metalloproteases that mediate the release of EGFR ligands 
from the cell surface (Schlange et al. 2007). Many studies indicate that Wnt and EGFR 
signaling crosstalk via receptor tyrosine kinase pathways. EGFR mediated PI3K/AKT 
activation promotes β-catenin transactivation and tumor cell invasion, suggesting that 
EGFR activation transactivate β-catenin activity via receptor tyrosine kinase pathways in 
tumor cells (Lu et al. 2003; Ji et al. 2009; Sharma et al. 2002; Agarwal et al. 2005). In breast 
cancers, upregulation of Wnt-1 induces EGFR and Erk1/2 MAPK activation. In APC 
deficient mice, Wnt activity causes EGFR/PI3K/AKT activation (Hu and Li 2010). 
Moreover, a recent study demonstrated that the high endogenous expression of AR in 
breast cancer cells potently and constitutively down-regulates the expression of Dikkopf1, 
a secreted inhibitor of the Wnt/β-catenin pathway (Baillo et al. 2011). These findings 
further illustrate the multifarious interactions between the Wnt/β-catenin and EGFR 
systems in cancer cells. Our current observations provide a novel point of convergence 
between EGFR and β-catenin pathways in human HCC cells, in this case through the 
regulation of the expression of the EGFR ligand AR by β-catenin signalling. 
β-catenin acts in conjunction with the Tcf family of transcription factors to activate the 
expression of specific oncogenes and thus promote cell proliferation (Moon et al. 2004, 
Coleman 2003). In 33–67% of HCC patients, nuclear and/or cellular accumulation of β-
catenin have been closely associated with clinico-pathological characteristics such as a 
poorly differentiated morphology, high proliferative activity, vascular invasion and dismal 
prognosis (Coleman 2003; Endo et al. 2000). In addition, mutation of β-catenin (leading to 
its nuclear and/or cytoplasmic accumulation) has been reported in 10–20% of all HCC, 
and in more than 40% of HCCs associated with hepatitis C virus infection (Hsu et al. 2000; 
Inagawa et al. 2002; Huang et al. 1999), but with lower frequency in other types of human 
cancers (Cieply et al. 2009; Sparks et al. 1998). Such oncogenic mutation of β-catenin 
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renders it capable of bypassing APC-targeted degradation and accumulating in the nucleus 
to form a complex with Tcf4, thereby aberrantly activating downstream transcriptional 
events (Huang et al. 1999, Rubinfeld et al. 1997). Thus, interfering with the Wnt/β-catenin 
signaling pathway may provide a potential opportunity for the development of novel and 
highly selective drugs for the treatment of HCC. Targeting of the aberrant activation of 
Wnt/β-catenin pathway has previously been proposed as a promising strategy in cancer 
therapy (Morin et al. 1997, You et al. 2004). A recent study reported the use of a high 
throughput screening assay to identify natural compounds that can disrupt the oncogenic 
Tcf4/β-catenin complex in vitro (Avila et al. 2006; Wei et al. 2010). Several small molecule 
antagonists such as PKF118-310, PKF115-584, CPG049090 selectively interfered with the 
binding of β-catenin and Tcf4, and also inhibited the proliferation of colon and prostate 
and HCC cancer cell lines in vitro and in vitro. (Wei et al. 2010). 
As previously mentioned several mechanisms account for β-catenin pathway activation 
in HCC cells (Nault and Zucman-Rossi 2011; Dahmanin et al. 2011; Bengochea et al. 2008; 
White et al. 2012; Yuzugullu et al. 2009; Nejak-Bowen and Monga 2011). In addition, 
signalling pathways commonly activated in HCC cells such as those triggered by FGF19, 
TGFβ or the HGF receptor MET, have been reported to stimulate β-catenin signalling 
(Sawey et al. 2011; Hoshida et al. 2009; Monga et al. 2002). Activation of β-catenin through 
the FGF19/FGFR4 system has been thoroughly characterized in human HCC and colon 
cancer cells (Sawey et al. 2011; Pai et al. 2008). This, together with previous evidences 
showing the ability of the closely-related FGFR1 receptor to up-regulate AR expression in 
epithelial cells (Bade et al. 2011), led us to examine whether AR could be a target of 
FGF19/FGFR4 signalling. Here we first demonstrate that FGF19 is a novel inducer of AR 
gene expression in human HCC cells. Moreover, the inhibitory effect of dominant negative 
ΔNTcf4 on FGF19 induced AR expression, as well as the attenuated response to FGF19 of 
AR promoter-reporter constructs with mutated TBE sites; strongly suggest that β-catenin 
signalling is involved in this response. FGF19 has been recently identified as a driver gene 
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in human hepatocarcinogenesis (Sawey et al. 2011). FGF19 gene expression is elevated in 
liver tumors correlating with a poor prognosis, and FGF19 neutralizing antibodies inhibit 
experimental HCC growth (Desnoyers et al. 2008; Miura et al. 2012). In HCC cells FGF19 
signals through the FGFR4/β-klotho complex, which is also frequently up-regulated in 
human HCC tissues and is emerging as a good candidate anti-tumor target (Bade et al. 
2011; Gauglhofer et al. 2011; Poh et al. 2012; French et al. 2012). Although the 
intracellular pro-tumorigenic mechanisms triggered by FGF19/FGFR4/β-klotho signaling 
are not completely known induction of cyclin D1 expression is considered a key event, and 
this effect also involved the activation of β-catenin signaling (Sawey et al. 2011). 
Interestingly, we found that knockdown of AR expression blunted the induction of cyclin 
D1 mediated by FGF19 in HCC cells. In line with this finding we also observed that upon 
EGFR inhibition, or in the presence of AR neutralizing antibodies, the proliferative effects 
of FGF19 on HCC cells were significatively attenuated. 
As known, FGFR4 is required for FGF19-mediated liver tumorigenesis in vivo and show 
that treatment with an FGFR4 neutralizing antibody (LD1) inhibited FGFR4-mediated 
signaling, proliferation, and colony formation in cell-based assays and tumor growth in 
preclinical models of HCC in vivo. Are also known that FGFR4 expression is elevated in 
several types of cancer, including liver cancer, as compared to normal tissues. These 
findings provide evidence for a modulatory role of FGFR4 in HCC development and 
progression and suggest that FGFR4 may be an important and novel therapeutic target in 
treating this disease (French et al. 2012). 
Taken together our results identify AR as a new downstream target of FGF19 in HCC 
cells, and reveal a functional cross-talk in which the AR/EGFR system mediates, and likely 
amplifies, the tumor-promoting effects of FGF19. Our finding that AR and FGF19 gene 
expression levels showed a positive correlation in human HCC tissues supports the clinical 
relevance for our experimental observations. Moreover, the increased expression of these 
two genes in a subclass of tumors corresponding to patients with poorer prognosis (Lee et 
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al. 2006) suggests their potential contribution to the progression of the disease. From a 
translational point of view, our observations also suggest that the efficacy of 
FGF19/FGFR4 targeted therapies that are currently being devised for HCC treatment 
(Desnoyers et al. 2008; Bade et al. 2011; French et al. 2012) could be enhanced by 
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1. AR is a transcriptional target of β-catenin in HCC cells. 
2. β-catenin-mediated AR expression participate in the pro-mitogenic effects of 
mutant β-catenin variant (T41A) in HCC cells. 
3. FGF19 is a novel agonist of AR expression in HCC cells through the activation of 
β-catenin signaling. 
4. FGF19-induced AR mediates in part the proliferative effects of FGF19 in HCC 
cells. 
5. AR and FGF19 gene expression levels showed a positive correlation and 
asociated with a poor prognosis in human HCC tissues supports the clinical 
relevance for our experimental observations.  
6. From a translational point of view, our observations also suggest that the efficacy 
of FGF19/FGFR4 targeted therapies that are currently being devised for HCC 
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